Analyst Target Signals
Showing 195 signals. Updated 2026-04-02. Highlighting BCYC.
Price$9.19
Signal$8.82|+4.2%|+046022-01-01 08:00
TargetsPT $26.00 | Cons $24.67
UpsideImp +194.8% | Cons +179.7%
Price$9.21
Signal$5.98|+54.0%|+046022-01-01 08:00
TargetsPT $15.00 | Cons $13.50
UpsideImp +150.8% | Cons +125.8%
Price$23.08
Signal$16.23|+42.2%|2026-01-06 20:49:28
Headline: Alumis price target raised to $50 from $25 at Oppenheimer
TargetsPT $50.00 | Cons $34.33
UpsideImp +208.1% | Cons +111.5%
Price$5.95
Signal$7.00|-14.9%|2026-01-08 17:46:51
Headline: Ardelyx price target raised to $19 from $16 at Raymond James
TargetsPT $19.00 | Cons $15.60
UpsideImp +171.6% | Cons +123.0%
Price$14.26
Signal$10.77|+32.4%|2026-01-08 14:44:28
Headline: Cullinan Therapeutics price target raised to $27 from $26 at H.C. Wainwright
TargetsPT $27.00 | Cons $31.00
UpsideImp +150.7% | Cons +187.8%
Price$0.78
Signal$0.99|-21.7%|2026-01-14 14:28:00
Headline: DA Davidson Reiterates Buy Rating on BRC Inc. (BRCC)
TargetsPT $2.50 | Cons $2.50
UpsideImp +151.6% | Cons +151.6%
Price$18.79
Signal$23.53|-20.1%|2026-01-20 16:24:40
Headline: FDA draft guidance favorable for Legend Biotech, says RBC Capital
TargetsPT $66.00 | Cons $62.17
UpsideImp +180.5% | Cons +164.3%
Price$3.66
Signal$3.64|+0.4%|2026-01-20 11:50:04
Headline: Atai Beckley initiated with a Buy at Guggenheim
TargetsPT $11.00 | Cons $12.33
UpsideImp +202.2% | Cons +238.7%
Price$4.62
Signal$2.10|+120.1%|2026-01-20 10:44:01
Headline: Opus Genetics initiated with a Buy at BTIG
TargetsPT $7.00 | Cons $7.00
UpsideImp +233.3% | Cons +233.3%
Price$8.02
Signal$7.59|+5.6%|2026-01-22 21:08:58
Headline: Arcturus Therapeutics initiated with a Buy at Roth Capital
TargetsPT $20.00 | Cons $37.00
UpsideImp +163.5% | Cons +387.5%
Price$14.51
Signal$16.73|-13.3%|2026-01-23 19:24:14
Headline: GH Research price target raised to $40 from $33 at RBC Capital
TargetsPT $40.00 | Cons $35.17
UpsideImp +139.1% | Cons +110.2%
Price$6.90
Signal$3.96|+74.2%|2026-01-23 11:24:34
Headline: Relmada Therapeutics assumed at Outperform from Market Perform at Leerink
TargetsPT $8.00 | Cons $8.50
UpsideImp +102.0% | Cons +114.6%
Price$76.03
Signal$36.35|+109.2%|2026-01-26 13:56:00
Headline: Piper Sandler on Nektar Therapeutics (NKTR): 'We See a Substantial Opportunity Into These De-Risked…
TargetsPT $105.00 | Cons $119.00
UpsideImp +188.9% | Cons +227.4%
Price$12.75
Signal$11.69|+9.1%|2026-01-28 23:12:24
Headline: Korro Bio upgraded to Overweight from Neutral at Piper Sandler
TargetsPT $30.00 | Cons $19.67
UpsideImp +156.6% | Cons +68.3%
Price$85.86
Signal$53.23|+61.3%|2026-01-29 13:06:01
Headline: Dianthus price target raised to $125 from $62 at Oppenheimer
TargetsPT $125.00 | Cons $80.20
UpsideImp +134.8% | Cons +50.7%
Price$4.51
Signal$4.26|+5.9%|2026-01-30 11:08:17
Headline: Perspective Therapeutics price target raised to $12 from $10 at H.C. Wainwright
TargetsPT $12.00 | Cons $11.00
UpsideImp +181.7% | Cons +158.2%
Price$6.66
Signal$10.27|-35.2%|2026-01-30 09:58:00
Headline: enGene initiated with a Buy at Jefferies
TargetsPT $28.00 | Cons $24.00
UpsideImp +172.6% | Cons +133.7%
Price$14.26
Signal$11.96|+19.2%|2026-02-02 00:19:56
Headline: Cullinan Therapeutics initiated with a Buy at Guggenheim
TargetsPT $30.00 | Cons $30.83
UpsideImp +150.8% | Cons +157.8%
Price$382.74
Signal$387.34|-1.2%|2026-02-04 23:07:34
Headline: AppLovin derating creates potential opportunity, says Morgan Stanley
TargetsPT $800.00 | Cons $755.85
UpsideImp +106.5% | Cons +95.1%
Price$5.41
Signal$6.42|-15.8%|2026-02-04 11:36:12
Headline: Compass Therapeutics price target raised to $13 from $10 at Canaccord
TargetsPT $13.00 | Cons $10.50
UpsideImp +102.5% | Cons +63.6%
Price$5.89
Signal$6.01|-2.0%|2026-02-09 11:32:07
Headline: Zura Bio initiated with an Outperform at Wedbush
TargetsPT $15.00 | Cons $15.00
UpsideImp +149.6% | Cons +149.6%
Price$76.03
Signal$52.62|+44.5%|2026-02-10 14:16:02
Headline: Nektar price target raised to $165 from $135 at H.C. Wainwright
TargetsPT $165.00 | Cons $131.40
UpsideImp +213.6% | Cons +149.7%
Price$67.78
Signal$75.92|-10.7%|2026-02-11 14:29:00
Headline: Bernstein Reiterates Outperform Rating on Robinhood Markets (HOOD)
TargetsPT $160.00 | Cons $137.71
UpsideImp +110.7% | Cons +81.4%
Price$382.74
Signal$372.29|+2.8%|2026-02-12 14:44:21
Headline: AppLovin price target raised to $775 from $750 at Scotiabank
TargetsPT $775.00 | Cons $690.93
UpsideImp +108.2% | Cons +85.6%
Price$9.21
Signal$7.47|+23.3%|2026-02-17 11:36:06
Headline: Vir Biotechnology price target raised to $26 from $24 at Barclays
TargetsPT $26.00 | Cons $20.50
UpsideImp +248.1% | Cons +174.4%
Price$5.59
Signal$5.71|-2.1%|2026-02-19 12:18:20
Headline: Verastem price target raised to $18 from $15 at Mizuho
TargetsPT $18.00 | Cons $15.00
UpsideImp +215.2% | Cons +162.7%
Price$104.54
Signal$99.29|+5.3%|2026-02-23 13:21:05
Headline: Nebius price target raised to $232 from $211 at Northland
TargetsPT $232.00 | Cons $156.33
UpsideImp +133.7% | Cons +57.4%
Price$9.21
Signal$7.43|+24.0%|2026-02-24 11:49:58
Headline: Vir Biotechnology price target raised to $24 from $20 at Morgan Stanley
TargetsPT $24.00 | Cons $20.67
UpsideImp +223.0% | Cons +178.2%
Price$71.78
Signal$82.62|-13.1%|2026-02-24 18:10:04
Headline: Jefferies trims Planet Fitness price target, sees 'strong buying opportunity'
TargetsPT $175.00 | Cons $134.00
UpsideImp +111.8% | Cons +62.2%
Price$9.21
Signal$9.33|-1.2%|2026-02-26 18:07:00
Headline: Vir Biotechnology (VIR) PT Raised to $20 at Leerink Partners
TargetsPT $20.00 | Cons $20.57
UpsideImp +114.5% | Cons +120.6%
Price$18.44
Signal$16.15|+14.2%|2026-03-02 22:37:00
Headline: Chardan Reiterates Buy Rating on Dyne Therapeutics (DYN)
TargetsPT $38.00 | Cons $37.60
UpsideImp +135.3% | Cons +132.8%
Price$16.62
Signal$17.67|-5.9%|2026-03-03 22:19:00
Headline: Truist Securities Reiterates Buy Rating on Sportradar Group AG (SRAD) following Q4 report
TargetsPT $32.00 | Cons $32.00
UpsideImp +81.1% | Cons +81.1%
Price$12.00
Signal$13.41|-10.5%|2026-03-03 14:49:00
Headline: Benchmark Reiterates Buy Rating on Surgery Partners (SGRY) Following Q4 Results
TargetsPT $30.00 | Cons $22.33
UpsideImp +123.7% | Cons +66.5%
Price$4.66
Signal$5.48|-14.9%|2026-03-03 14:30:00
Headline: Larimar Therapeutics (LRMR) PT Raised to $12 at Wedbush
TargetsPT $12.00 | Cons $9.50
UpsideImp +119.2% | Cons +73.5%
Price$98.17
Signal$97.68|+0.5%|2026-03-03 14:27:00
Headline: Stifel Reiterates Buy Rating on Credo Technology Group Holding Ltd. (CRDO) Following Solid Print
TargetsPT $200.00 | Cons $213.50
UpsideImp +104.8% | Cons +118.6%
Price$24.06
Signal$26.73|-10.0%|2026-03-03 11:07:00
Headline: Jefferies Starts SpyGlass Pharma (SGP) at Buy
TargetsPT $62.00 | Cons $62.00
UpsideImp +131.9% | Cons +131.9%
Price$22.39
Signal$23.82|-6.0%|2026-03-03 10:48:00
Headline: DraftKings Inc. (DKNG) PT Raised to $50 at BMO Capital, Top Pick
TargetsPT $50.00 | Cons $37.61
UpsideImp +109.9% | Cons +57.9%
Price$8.02
Signal$7.42|+8.0%|2026-03-04 12:52:00
Headline: '2026 will be a stock-moving year for ArthroCare (ARTC)'; PT Lowered at Piper Sandler
TargetsPT $25.00 | Cons $22.50
UpsideImp +236.9% | Cons +203.2%
Price$9.21
Signal$9.13|+0.9%|2026-03-04 11:41:00
Headline: Vir Biotechnology (VIR) PT Raised to $20 at H.C. Wainwright
TargetsPT $20.00 | Cons $21.29
UpsideImp +119.1% | Cons +133.2%
Price$11.90
Signal$13.32|-10.7%|2026-03-04 11:41:00
Headline: US GoldMining Inc. (USGO) PT Raised to $30.75 at H.C. Wainwright
TargetsPT $30.75 | Cons $30.75
UpsideImp +130.9% | Cons +130.9%
Price$15.33
Signal$13.01|+17.8%|2026-03-05 17:55:00
Headline: Jefferies Reiterates Buy Rating on Sable Offshore Corp. (SOC) amid DOJ formal opinion
TargetsPT $28.00 | Cons $27.00
UpsideImp +115.2% | Cons +107.5%
Price$5.59
Signal$6.18|-9.5%|2026-03-05 15:06:00
Headline: Jefferies Reiterates Buy Rating on Verastem (VSTM); "catalyst-rich 2026"
TargetsPT $19.00 | Cons $16.00
UpsideImp +207.4% | Cons +158.9%
Price$13.60
Signal$16.52|-17.7%|2026-03-05 14:23:00
Headline: Rosenblatt Reiterates Buy Rating on Rigetti Computing Inc. (RGTI), raises rev estimate
TargetsPT $40.00 | Cons $38.33
UpsideImp +142.2% | Cons +132.1%
Price$3.66
Signal$3.39|+7.8%|2026-03-06 20:37:00
Headline: Jefferies Reiterates Buy Rating on atai Life Sciences N.V (ATAI): "keen on ATAI's robust BPL-003 Pha…
TargetsPT $10.00 | Cons $11.75
UpsideImp +195.0% | Cons +246.6%
Price$16.05
Signal$14.07|+14.1%|2026-03-06 17:15:00
Headline: Jade Biosciences (JBIO) PT Raised to $40 at Stifel: "We like the setup for JADE101"
TargetsPT $40.00 | Cons $31.00
UpsideImp +184.4% | Cons +120.4%
Price$23.67
Signal$23.67|0.0%|2026-03-06 12:32:00
Headline: Badger Infrastructure Solutions Ltd (BDGI:CN) (BADFF) PT Lowered at BMO Capital
TargetsPT $80.00 | Cons $43.52
UpsideImp +238.0% | Cons +83.9%
Price$14.51
Signal$15.34|-5.4%|2026-03-06 12:04:00
Headline: GH Research PLC (GHRS) PT Raised to $32 at Needham
TargetsPT $32.00 | Cons $35.67
UpsideImp +108.7% | Cons +132.6%
Price$2.60
Signal$2.32|+12.0%|2026-03-09 20:22:00
Headline: Baird Reiterates Outperform Rating on Editas Medicine (EDIT) following earnings
TargetsPT $6.00 | Cons $6.00
UpsideImp +158.6% | Cons +158.6%
Price$17.11
Signal$17.69|-3.2%|2026-03-09 11:11:00
Headline: Wells Fargo Upgrades uniQure BV (QURE) to Overweight
TargetsPT $60.00 | Cons $41.80
UpsideImp +239.3% | Cons +136.4%
Price$5.71
Signal$9.51|-40.0%|2026-03-09 14:57:00
Headline: Raymond James Reiterates Strong Buy Rating on Kalaris (KLRS)
TargetsPT $23.00 | Cons $21.00
UpsideImp +141.9% | Cons +120.8%
Price$6.66
Signal$7.79|-14.6%|2026-03-09 14:16:00
Headline: Raymond James Reiterates Strong Buy Rating on Engene Holdings Inc. (ENGN) following Q1 results
TargetsPT $27.00 | Cons $24.60
UpsideImp +246.6% | Cons +215.8%
Price$23.67
Signal$23.67|0.0%|2026-03-09 12:40:00
Headline: AltaGas Ltd. (ALA:CN) (ATGFF) PT Raised to Cdn$49 at BMO Capital
TargetsPT $49.00 | Cons $39.09
UpsideImp +107.0% | Cons +65.1%
Price$7.15
Signal$7.33|-2.5%|2026-03-10 20:06:00
Headline: Raymond James Starts Climb Bio (CLYM) at Strong Buy
TargetsPT $25.00 | Cons $18.00
UpsideImp +241.1% | Cons +145.6%
Price$88.76
Signal$83.89|+5.8%|2026-03-10 18:28:00
Headline: Truist Securities Reiterates Buy Rating on BioNTech (BNTX) following earnings, management changes
TargetsPT $155.00 | Cons $138.71
UpsideImp +84.8% | Cons +65.3%
Price$6.04
Signal$5.99|+0.9%|2026-03-10 16:20:00
Headline: H.C. Wainwright Reiterates Buy Rating on Q32 Bio Inc. (QTTB): "2026 should be highlighted by key cli…
TargetsPT $13.00 | Cons $13.00
UpsideImp +117.0% | Cons +117.0%
Price$18.79
Signal$19.56|-3.9%|2026-03-10 16:10:00
Headline: Truist Securities Reiterates Buy Rating on Legend Biotech Corp. (LEGN): "infer from comments that Ra…
TargetsPT $70.00 | Cons $58.60
UpsideImp +257.9% | Cons +199.6%
Price$6.84
Signal$8.11|-15.6%|2026-03-10 13:16:00
Headline: Craig-Hallum Reiterates Buy Rating on Jumia Technologies (JMIA): "we expect quarters to start to sta…
TargetsPT $18.00 | Cons $17.33
UpsideImp +122.1% | Cons +113.8%
Price$2.45
Signal$3.14|-21.9%|2026-03-10 13:08:00
Headline: DA Davidson Reiterates Buy Rating on Repay (RPAY) Following Q4 Results
TargetsPT $9.00 | Cons $6.83
UpsideImp +187.1% | Cons +117.9%
Price$14.51
Signal$15.81|-8.2%|2026-03-10 10:40:00
Headline: GH Research PLC (GHRS) PT Raised to $34 at Guggenheim
TargetsPT $34.00 | Cons $36.50
UpsideImp +115.1% | Cons +130.9%
Price$9.19
Signal$11.03|-16.7%|2026-03-10 10:40:00
Headline: Zevra Therapeutics, Inc. (ZVRA) PT Raised to $23 at Guggenheim
TargetsPT $23.00 | Cons $24.25
UpsideImp +108.5% | Cons +119.9%
Price$7.81
Signal$9.28|-15.8%|2026-03-10 10:22:00
Headline: ARS Pharmaceuticals Inc (SPRY) PT Raised to $26 at Leerink Partners
TargetsPT $26.00 | Cons $29.33
UpsideImp +180.2% | Cons +216.1%
Price$26.00
Signal$27.23|-4.5%|2026-03-10 10:12:00
Headline: H.C. Wainwright Reiterates Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
TargetsPT $56.00 | Cons $54.00
UpsideImp +105.7% | Cons +98.3%
Price$5.95
Signal$5.66|+5.1%|2026-03-12 19:10:00
Headline: Leerink Partners Reiterates Outperform Rating on Ardelyx, Inc (ARDX) following conference
TargetsPT $17.00 | Cons $17.00
UpsideImp +200.4% | Cons +200.4%
Price$33.61
Signal$35.47|-5.2%|2026-03-12 16:48:00
Headline: Jefferies Reiterates Buy Rating on Viking Therapeutic (VKTX): "VKTX is in an execution mode this yea…
TargetsPT $101.00 | Cons $103.00
UpsideImp +184.7% | Cons +190.4%
Price$1.61
Signal$1.70|-5.7%|2026-03-12 16:26:00
Headline: H.C. Wainwright Reiterates Buy Rating on Lexicon Pharmaceuticals (LXRX): "significant upside potenti…
TargetsPT $6.00 | Cons $6.00
UpsideImp +252.5% | Cons +252.5%
Price$16.59
Signal$15.58|+6.5%|2026-03-12 15:53:00
Headline: H.C. Wainwright Reiterates Buy Rating on Pharming Group (PHAR): "well positioned to drive value"
TargetsPT $37.00 | Cons $39.50
UpsideImp +137.5% | Cons +153.5%
Price$21.73
Signal$21.36|+1.7%|2026-03-12 14:39:00
Headline: Leerink Partners Reiterates Outperform Rating on Ultragenyx Pharma (RARE): "encouraged by this clini…
TargetsPT $60.00 | Cons $49.90
UpsideImp +180.9% | Cons +133.6%
Price$0.66
Signal$0.95|-30.4%|2026-03-12 14:37:00
Headline: Leerink Partners Reiterates Outperform Rating on Tenaya Therapeutics Inc (TNYA): "remains on track t…
TargetsPT $2.00 | Cons $2.33
UpsideImp +110.5% | Cons +145.3%
Price$3.51
Signal$3.88|-9.7%|2026-03-12 14:07:00
Headline: LifeMD Inc (LFMD) PT Raised to $10 at Freedom Capital Markets
TargetsPT $10.00 | Cons $8.50
UpsideImp +157.7% | Cons +119.1%
Price$1.74
Signal$1.70|+2.4%|2026-03-12 13:46:00
Headline: Stifel Reiterates Buy Rating on Codexis, Inc. (CDXS): "remains an interesting small cap idea"
TargetsPT $5.00 | Cons $5.00
UpsideImp +194.1% | Cons +194.1%
Price$2.99
Signal$3.36|-11.0%|2026-03-13 17:05:00
Headline: Morgan Stanley Reiterates Overweight Rating on Sana Biotechnology (SANA) after "meaningful platform…
TargetsPT $12.00 | Cons $9.00
UpsideImp +257.1% | Cons +167.9%
Price$4.03
Signal$4.19|-3.8%|2026-03-13 14:15:00
Headline: Sono-Tek (SOTK) PT Raised to $8.50 at Oak Ridge Financial
TargetsPT $8.50 | Cons $8.50
UpsideImp +102.9% | Cons +102.9%
Price$1.19
Signal$1.45|-18.0%|2026-03-13 13:28:00
Headline: DA Davidson Reiterates Buy Rating on Open Lending (LPRO)
TargetsPT $4.00 | Cons $4.00
UpsideImp +176.8% | Cons +176.8%
Price$38.99
Signal$38.99|0.0%|2026-03-13 13:28:00
Headline: ServiceTitan (TTAN) PT Raised to $135 at TD Cowen
TargetsPT $135.00 | Cons $106.67
UpsideImp +246.2% | Cons +173.6%
Price$1.41
Signal$1.38|+2.2%|2026-03-13 13:15:00
Headline: Stifel Reiterates Buy Rating on Century Casinos (CNTY) following Q4 report
TargetsPT $3.00 | Cons $2.50
UpsideImp +117.4% | Cons +81.2%
Price$2.73
Signal$3.01|-9.2%|2026-03-13 13:05:00
Headline: Jefferies Reiterates Buy Rating on AC Immune SA (ACIU): '2025 financials largely immaterial'
TargetsPT $7.00 | Cons $7.00
UpsideImp +132.9% | Cons +132.9%
Price$11.70
Signal$10.81|+8.2%|2026-03-13 11:59:00
Headline: Relay Therapeutics (RLAY) PT Raised to $22 at Guggenheim
TargetsPT $22.00 | Cons $16.33
UpsideImp +103.4% | Cons +51.0%
Price$12.75
Signal$11.50|+10.9%|2026-03-13 08:26:00
Headline: Raymond James Upgrades Korro Bio Inc. (KRRO) to Outperform
TargetsPT $23.00 | Cons $20.29
UpsideImp +100.0% | Cons +76.4%
Price$9.89
Signal$9.31|+6.2%|2026-03-13 10:30:00
Headline: Prothena (PRTA) Reiterated at Market Outperform by Citizens After Fireside Chat
TargetsPT $19.00 | Cons $24.83
UpsideImp +104.1% | Cons +166.7%
Price$8.36
Signal$9.45|-11.5%|2026-03-16 16:32:00
Headline: VNET Group Inc (VNET) PT Raised to $23.55 at Jefferies, 'Growth to Accelerate', 'Still our top pick'
TargetsPT $23.55 | Cons $23.55
UpsideImp +149.2% | Cons +149.2%
Price$2.50
Signal$2.86|-12.6%|2026-03-16 15:40:00
Headline: H.C. Wainwright Reiterates Buy Rating on NovaBridge Biosciences (NBP) following FDA meeting feedback
TargetsPT $9.00 | Cons $9.00
UpsideImp +214.7% | Cons +214.7%
Price$7.15
Signal$7.12|+0.4%|2026-03-17 20:06:00
Headline: Truist Securities Starts Climb Bio (CLYM) at Buy
TargetsPT $17.00 | Cons $17.67
UpsideImp +138.8% | Cons +148.2%
Price$4.51
Signal$5.09|-11.4%|2026-03-17 12:35:00
Headline: Truist Reiterates Buy Rating on Perspective Therapeutics Inc (CATX)
TargetsPT $12.00 | Cons $12.20
UpsideImp +135.8% | Cons +139.7%
Price$54.14
Signal$56.88|-4.8%|2026-03-17 12:29:00
Headline: Structure Therapeutics (GPCR) PT Raised to $145 at BMO Capital
TargetsPT $145.00 | Cons $116.71
UpsideImp +154.9% | Cons +105.2%
Price$4.92
Signal$5.13|-4.2%|2026-03-17 12:29:00
Headline: Morgan Stanley on Bicycle Therapeutics (BCYC): program deprioritization 'disappointing,' but 'right…
TargetsPT $13.00 | Cons $11.00
UpsideImp +153.4% | Cons +114.4%
Price$4.45
Signal$4.61|-3.4%|2026-03-18 14:16:00
Headline: CytomX Therapeutics (CTMX) PT Raised to $16 at Jefferies: 'buying opportunity here'
TargetsPT $16.00 | Cons $11.60
UpsideImp +247.4% | Cons +151.9%
Price$14.51
Signal$15.80|-8.2%|2026-01-05 14:59:00
Headline: Guggenheim Reiterates Buy Rating on GH Research PLC (GHRS) Post Mgmt Call
TargetsPT $29.00 | Cons $34.20
UpsideImp +83.5% | Cons +116.4%
Price$5.41
Signal$4.89|+10.5%|2026-01-06 15:11:00
Headline: Raymond James Reiterates Outperform Rating on Compass Therapeutics (CMPX)
TargetsPT $9.00 | Cons $9.67
UpsideImp +84.0% | Cons +97.7%
Price$85.86
Signal$38.09|+125.4%|2026-01-08 12:54:20
Headline: Dianthus price target raised to $63 from $56 at Truist
TargetsPT $63.00 | Cons $69.00
UpsideImp +65.4% | Cons +81.1%
Price$9.02
Signal$12.14|-25.7%|2026-01-20 11:04:33
Headline: Ondas price target raised to $25 from $12 at H.C. Wainwright
TargetsPT $25.00 | Cons $16.43
UpsideImp +106.0% | Cons +35.4%
Price$4.45
Signal$5.39|-17.5%|2026-01-20 11:48:45
Headline: CytomX Therapeutics price target raised to $10 from $6.50 at Piper Sandler
TargetsPT $10.00 | Cons $8.75
UpsideImp +85.5% | Cons +62.3%
Price$55.55
Signal$54.59|+1.8%|2026-01-20 10:05:41
Headline: BioMarin upgraded to Buy from Hold at Canaccord
TargetsPT $98.00 | Cons $82.92
UpsideImp +79.5% | Cons +51.9%
Price$16.62
Signal$18.25|-8.9%|2026-01-22 11:43:34
Headline: Sportradar price target raised, named a Best Idea for 2026 at Guggenheim
TargetsPT $35.00 | Cons $32.00
UpsideImp +91.8% | Cons +75.3%
Price$11.70
Signal$7.43|+57.5%|2026-01-26 11:22:55
Headline: Relay Therapeutics upgraded to Outperform from Perform at Oppenheimer
TargetsPT $14.00 | Cons $13.50
UpsideImp +88.4% | Cons +81.7%
Price$33.36
Signal$36.07|-7.5%|2026-01-27 21:26:51
Headline: MBX Biosciences initiated with an Overweight at Barclays
TargetsPT $66.00 | Cons $53.33
UpsideImp +83.0% | Cons +47.9%
Price$12.75
Signal$10.74|+18.7%|2026-01-27 21:10:15
Headline: Korro Bio upgraded to Overweight from Neutral at Cantor Fitzgerald
TargetsPT $21.00 | Cons $21.50
UpsideImp +95.5% | Cons +100.2%
Price$5.95
Signal$7.80|-23.7%|2026-01-27 11:23:17
Headline: Ardelyx price target raised to $15 from $8 at Jefferies
TargetsPT $15.00 | Cons $15.50
UpsideImp +92.3% | Cons +98.7%
Price$4.45
Signal$6.07|-26.7%|2026-02-04 10:46:04
Headline: CytomX Therapeutics price target raised to $10 from $8 at Barclays
TargetsPT $10.00 | Cons $10.00
UpsideImp +64.7% | Cons +64.7%
Price$14.00
Signal$20.50|-31.7%|2026-02-19 11:28:43
Headline: Grupo Aeromexico price target raised to $32 from $28 at Barclays
TargetsPT $32.00 | Cons $31.33
UpsideImp +56.1% | Cons +52.8%
Price$174.98
Signal$191.16|-8.5%|2026-02-23 15:15:00
Headline: Cantor Fitzgerald Reiterates Overweight Rating on NVIDIA (NVDA), Expects Beat and Raise Quarter
TargetsPT $400.00 | Cons $272.54
UpsideImp +109.2% | Cons +42.6%
Price$10.54
Signal$15.71|-32.9%|2026-02-23 12:26:14
Headline: PicPay initiated with an Outperform at Mizuho
TargetsPT $30.00 | Cons $23.67
UpsideImp +91.0% | Cons +50.7%
Price$3.82
Signal$5.17|-26.2%|2026-02-23 06:49:00
Headline: Citizens Starts MiMedx Group (MDXG) at Market Outperform
TargetsPT $10.00 | Cons $10.00
UpsideImp +93.4% | Cons +93.4%
Price$8.15
Signal$9.82|-17.0%|2026-02-26 11:05:00
Headline: H.C. Wainwright Upgrades Joby Aviation Inc (JOBY) to Buy
TargetsPT $18.00 | Cons $15.30
UpsideImp +83.3% | Cons +55.8%
Price$19.76
Signal$21.00|-5.9%|2026-03-02 22:08:00
Headline: Jefferies Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
TargetsPT $40.00 | Cons $34.40
UpsideImp +90.5% | Cons +63.8%
Price$2.39
Signal$1.79|+33.5%|2026-03-03 15:15:00
Headline: Clear Street Reiterates Buy Rating on Prairie Operating Co (PROP) amid CEO resignation
TargetsPT $3.50 | Cons $2.75
UpsideImp +95.5% | Cons +53.6%
Price$55.55
Signal$59.74|-7.0%|2026-03-03 11:12:00
Headline: BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Barclays
TargetsPT $105.00 | Cons $85.43
UpsideImp +75.8% | Cons +43.0%
Price$18.77
Signal$20.25|-7.3%|2026-03-03 11:04:00
Headline: Ouster Inc. (OUST) PT Raised to $40 at Oppenheimer
TargetsPT $40.00 | Cons $37.00
UpsideImp +97.5% | Cons +82.7%
Price$26.92
Signal$27.72|-2.9%|2026-03-04 21:46:00
Headline: Oculis Holding AG (OCS) PT Raised to $50 at Stifel
TargetsPT $50.00 | Cons $45.67
UpsideImp +80.4% | Cons +64.8%
Price$66.76
Signal$60.72|+9.9%|2026-03-04 15:12:00
Headline: Power Solutions (PSIX) PT Raised to $107 at Freedom Capital Markets
TargetsPT $107.00 | Cons $104.26
UpsideImp +76.2% | Cons +71.7%
Price$35.08
Signal$39.62|-11.4%|2026-03-04 11:41:00
Headline: Harrow Health (HROW) PT Raised to $70 at H.C. Wainwright
TargetsPT $70.00 | Cons $74.50
UpsideImp +76.7% | Cons +88.1%
Price$174.98
Signal$180.10|-2.8%|2026-03-05 15:31:00
Headline: NVIDIA (NVDA) PT Raised to $360 at Tigress Financial Partners
TargetsPT $360.00 | Cons $277.82
UpsideImp +99.9% | Cons +54.3%
Price$33.36
Signal$28.78|+15.9%|2026-03-09 12:57:00
Headline: Truist Securities Reiterates Buy Rating on MBX Biosciences Inc (MBX)
TargetsPT $50.00 | Cons $55.33
UpsideImp +73.7% | Cons +92.3%
Price$71.78
Signal$76.88|-6.6%|2026-03-10 14:08:00
Headline: Morgan Stanley Reiterates Overweight Rating on Planet Fitness (PLNT) amid CFO transition
TargetsPT $117.00 | Cons $132.43
UpsideImp +52.2% | Cons +72.3%
Price$24.51
Signal$28.06|-12.7%|2026-03-10 13:24:00
Headline: Cantor Fitzgerald Reiterates Overweight Rating on Septerna Inc (SEPN)
TargetsPT $60.00 | Cons $39.00
UpsideImp +113.8% | Cons +39.0%
Price$14.26
Signal$15.11|-5.6%|2026-03-10 13:18:00
Headline: Cullinan Oncology Inc. (CGEM) PT Raised to $28 at Stifel
TargetsPT $28.00 | Cons $30.43
UpsideImp +85.4% | Cons +101.4%
Price$1.84
Signal$2.52|-27.2%|2026-03-10 12:53:00
Headline: 3D Systems (DDD) PT Raised to $5 at Cantor Fitzgerald Following 'Respectable' Q4 Results
TargetsPT $5.00 | Cons $5.00
UpsideImp +98.4% | Cons +98.4%
Price$46.43
Signal$52.03|-10.8%|2026-03-10 11:21:00
Headline: Tempus AI Inc (TEM) PT Raised to $95 at H.C. Wainwright
TargetsPT $95.00 | Cons $87.11
UpsideImp +82.6% | Cons +67.4%
Price$143.14
Signal$162.32|-11.8%|2026-03-11 14:27:00
Headline: Deutsche Bank Reiterates Buy Rating on Oracle (ORCL) following Q3 results: "plenty to like in this p…
TargetsPT $300.00 | Cons $280.79
UpsideImp +84.8% | Cons +73.0%
Price$4.62
Signal$4.99|-7.4%|2026-03-11 13:17:00
Headline: Craig-Hallum Reiterates Buy Rating on Opus Genetics (IRD): "continue to see significant upside oppor…
TargetsPT $9.00 | Cons $7.67
UpsideImp +80.4% | Cons +53.7%
Price$8.15
Signal$10.23|-20.3%|2026-03-12 10:44:00
Headline: H.C. Wainwright Reiterates Buy Rating on Joby Aviation Inc (JOBY)
TargetsPT $18.00 | Cons $15.75
UpsideImp +76.0% | Cons +54.0%
Price$6.71
Signal$6.63|+1.2%|2026-03-13 17:28:00
Headline: Clear Street Reiterates Hold Rating on Runway Grouwth Finance Corp. (RWAY): 'We expect near-term por…
TargetsPT $10.00 | Cons $10.83
UpsideImp +50.8% | Cons +63.3%
Price$76.03
Signal$73.27|+3.8%|2026-03-13 16:39:00
Headline: Nektar Therapeutics (NKTR) PT Raised to $140 at Oppenheimer
TargetsPT $140.00 | Cons $136.40
UpsideImp +91.1% | Cons +86.2%
Price$3.11
Signal$4.16|-25.2%|2026-03-13 13:15:00
Headline: Funko (FNKO) PT Raised to $6.50 at Texas Capital Securities
TargetsPT $6.50 | Cons $6.50
UpsideImp +56.3% | Cons +56.3%
Price$5.60
Signal$5.17|+8.3%|2026-03-16 15:22:00
Headline: H.C. Wainwright Reiterates Buy Rating on Savara (SVRA): 'well positioned ahead of the August PDUFA d…
TargetsPT $10.00 | Cons $10.25
UpsideImp +93.4% | Cons +98.2%
Price$23.67
Signal$23.67|0.0%|2026-03-16 14:42:00
Headline: Jefferies Reiterates Buy Rating on Forgent Power Solutions (FPS): 'encouraged' by performance amid c…
TargetsPT $44.00 | Cons $37.66
UpsideImp +85.9% | Cons +59.1%
Price$3.01
Signal$2.74|+10.1%|2026-03-16 14:21:00
Headline: Leerink Partners Reiterates Outperform Rating on Eledon Pharamceuticals (ELDN)
TargetsPT $5.00 | Cons $5.00
UpsideImp +82.8% | Cons +82.8%
Price$35.08
Signal$34.68|+1.2%|2026-03-18 16:00:00
Headline: BTIG Reiterates Buy Rating on Harrow Health (HROW) ahead of presentations
TargetsPT $63.00 | Cons $72.20
UpsideImp +81.7% | Cons +108.2%
Price$5.36
Signal$10.83|-50.6%|+046027-01-01 08:00
TargetsPT $26.00 | Cons $11.92
UpsideImp +140.1% | Cons +10.1%
Price$23.67
Signal$23.67|0.0%|2026-01-12 13:45:00
Headline: CAE Inc. (CAE:CN) (CAE) PT Raised to Cdn$46 at RBC Capital
TargetsPT $46.00 | Cons $35.19
UpsideImp +94.3% | Cons +48.7%
Price$36.75
Signal$33.91|+8.4%|2026-01-13 10:57:06
Headline: Versant initiated with an Outperform at Wolfe Research
TargetsPT $52.00 | Cons $52.00
UpsideImp +53.3% | Cons +53.3%
Price$98.17
Signal$156.84|-37.4%|2026-01-15 11:35:17
Headline: Credo Technology price target raised to $260 from $220 at Barclays
TargetsPT $260.00 | Cons $222.50
UpsideImp +65.8% | Cons +41.9%
Price$33.36
Signal$40.91|-18.5%|2026-01-16 11:33:00
Headline: MBX Biosciences Inc (MBX) PT Raised to $88 at Guggenheim
TargetsPT $88.00 | Cons $50.80
UpsideImp +115.1% | Cons +24.2%
Price$101.92
Signal$98.55|+3.4%|2026-01-16 09:09:00
Headline: Citi Upgrades Endeavour Group Ltd (EDV:AU) to Buy
TargetsPT $200.00 | Cons $106.40
UpsideImp +102.9% | Cons +8.0%
Price$16.62
Signal$18.25|-8.9%|2026-01-21 21:10:09
Headline: Sportradar initiated with a Buy at Stifel
TargetsPT $28.00 | Cons $32.00
UpsideImp +53.4% | Cons +75.3%
Price$12.75
Signal$11.69|+9.1%|2026-01-29 11:08:52
Headline: Korro Bio upgraded to Buy from Neutral at H.C. Wainwright
TargetsPT $20.00 | Cons $19.67
UpsideImp +71.1% | Cons +68.3%
Price$32.00
Signal$26.61|+20.3%|2026-02-02 10:58:25
Headline: Rapport Therapeutics initiated with an Overweight at Wells Fargo
TargetsPT $43.00 | Cons $42.33
UpsideImp +61.6% | Cons +59.1%
Price$67.78
Signal$82.82|-18.2%|2026-02-09 11:07:38
Headline: Robinhood upgraded to Outperform from Peer Perform at Wolfe Research
TargetsPT $125.00 | Cons $143.69
UpsideImp +50.9% | Cons +73.5%
Price$12.75
Signal$11.24|+13.5%|2026-02-18 21:23:00
Headline: Clear Street Upgrades Korro Bio Inc. (KRRO) to Buy
TargetsPT $18.00 | Cons $19.43
UpsideImp +60.2% | Cons +72.9%
Price$4.50
Signal$4.02|+12.0%|2026-02-19 11:55:08
Headline: Fossil initiated with an Outperform at Northland
TargetsPT $7.00 | Cons $7.00
UpsideImp +74.1% | Cons +74.1%
Price$105.23
Signal$76.96|+36.7%|2026-02-23 13:59:06
Headline: Marvell price target raised to $120 from $115 at UBS
TargetsPT $120.00 | Cons $117.68
UpsideImp +55.9% | Cons +52.9%
Price$10.54
Signal$16.15|-34.7%|2026-02-24 11:08:00
Headline: BofA Securities Starts PicPay (PICS) at Buy
TargetsPT $27.00 | Cons $24.50
UpsideImp +67.2% | Cons +51.7%
Price$174.98
Signal$182.02|-3.9%|2026-03-02 15:49:00
Headline: Baird Reiterates Outperform Rating on NVIDIA (NVDA) following Coherent investment
TargetsPT $300.00 | Cons $276.63
UpsideImp +64.8% | Cons +52.0%
Price$22.16
Signal$15.98|+38.7%|2026-03-03 17:00:00
Headline: Jefferies Reiterates Buy Rating on Sarepta Therapeutics (SRPT); cites as potential "recovery story"
TargetsPT $30.00 | Cons $22.89
UpsideImp +87.8% | Cons +43.3%
Price$5.04
Signal$4.10|+22.9%|2026-03-03 19:23:00
Headline: BTIG Reiterates Buy Rating on Sophia Genetics SA (SOPH)
TargetsPT $7.00 | Cons $7.00
UpsideImp +70.7% | Cons +70.7%
Price$174.98
Signal$179.72|-2.6%|2026-03-03 14:05:00
Headline: NVIDIA (NVDA) PT Raised to $300 at Wedbush
TargetsPT $300.00 | Cons $277.46
UpsideImp +66.9% | Cons +54.4%
Price$4.39
Signal$5.27|-16.7%|2026-03-03 11:25:00
Headline: Gray Television (GTN) PT Raised to $8 at Guggenheim
TargetsPT $8.00 | Cons $8.00
UpsideImp +51.8% | Cons +51.8%
Price$5.41
Signal$5.53|-2.3%|2026-03-05 21:33:00
Headline: Compass Therapeutics (CMPX) PT Raised to $9 at Jefferies
TargetsPT $9.00 | Cons $11.00
UpsideImp +62.7% | Cons +98.9%
Price$67.78
Signal$79.80|-15.1%|2026-03-05 16:46:00
Headline: BofA Securities Reiterates Buy Rating on Robinhood Markets (HOOD) following Take Flight event
TargetsPT $122.00 | Cons $132.13
UpsideImp +52.9% | Cons +65.6%
Price$208.82
Signal$234.34|-10.9%|2026-03-05 15:02:00
Headline: Jefferies Reiterates Buy Rating on HEICO (HEI) following 10-Q
TargetsPT $400.00 | Cons $387.50
UpsideImp +70.7% | Cons +65.4%
Price$105.23
Signal$91.36|+15.2%|2026-03-06 14:44:00
Headline: Marvell (MRVL) PT Raised to $164 at Craig-Hallum
TargetsPT $164.00 | Cons $120.68
UpsideImp +79.5% | Cons +32.1%
Price$4.77
Signal$5.45|-12.6%|2026-03-06 14:19:00
Headline: Benchmark Reiterates Buy Rating on Janus Int'l Group, Inc. (JBI), Estimates Unchanged
TargetsPT $9.00 | Cons $9.00
UpsideImp +65.1% | Cons +65.1%
Price$24.73
Signal$21.69|+14.0%|2026-03-09 16:04:00
Headline: Adeia (ADEA) PT Raised to $40 at Rosenblatt following AMD agreement
TargetsPT $40.00 | Cons $30.00
UpsideImp +84.4% | Cons +38.3%
Price$3.71
Signal$3.71|0.0%|2026-03-10 13:07:00
Headline: DA Davidson Reiterates Neutral Rating on RideNow Group (RDNW) as Momentum Continues
TargetsPT $6.00 | Cons $6.00
UpsideImp +61.7% | Cons +61.7%
Price$9.02
Signal$9.94|-9.3%|2026-03-10 10:16:00
Headline: H.C. Wainwright Reiterates Buy Rating on Ondas Holdings Inc. (ONDS)
TargetsPT $17.00 | Cons $15.63
UpsideImp +71.0% | Cons +57.2%
Price$5.16
Signal$5.58|-7.5%|2026-03-10 10:06:00
Headline: Deutsche Bank Upgrades Teladoc (TDOC) to Buy
TargetsPT $11.00 | Cons $7.90
UpsideImp +97.3% | Cons +41.7%
Price$22.16
Signal$17.04|+30.0%|2026-03-12 21:06:00
Headline: Sarepta Therapeutics (SRPT) PT Raised to $31 at Mizuho
TargetsPT $31.00 | Cons $24.50
UpsideImp +81.9% | Cons +43.8%
Price$26.13
Signal$26.19|-0.2%|2026-03-12 14:23:00
Headline: UBS Reiterates Buy Rating on Life Time Group Holdings Inc (LTH)
TargetsPT $43.00 | Cons $41.33
UpsideImp +64.2% | Cons +57.8%
Price$174.98
Signal$184.43|-5.1%|2026-03-12 13:28:00
Headline: Cantor Fitzgerald Reiterates Overweight Rating on NVIDIA (NVDA) Ahead of GTC Event
TargetsPT $300.00 | Cons $278.59
UpsideImp +62.7% | Cons +51.1%
Price$87.12
Signal$90.02|-3.2%|2026-03-12 09:56:00
Headline: Rhythm Pharmaceuticals (RYTM) PT Raised to $143 at Wells Fargo
TargetsPT $143.00 | Cons $140.18
UpsideImp +58.9% | Cons +55.7%
Price$6.90
Signal$5.91|+16.8%|2026-03-13 18:49:00
Headline: Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD): pullback 'a buying opprotuni…
TargetsPT $10.00 | Cons $9.00
UpsideImp +69.2% | Cons +52.3%
Price$104.93
Signal$107.97|-2.8%|2026-03-13 17:09:00
Headline: Stifel Reiterates Buy Rating on Colliers International (CIGI) amid Savills acquisition of Eastdil
TargetsPT $175.00 | Cons $182.60
UpsideImp +62.1% | Cons +69.1%
Price$51.15
Signal$38.01|+34.6%|2026-03-13 13:26:00
Headline: BTIG Reiterates Buy Rating on Oruka Therapeutics (ORKA): 'Commercial Precedents Continue to Read Thr…
TargetsPT $73.00 | Cons $55.86
UpsideImp +92.0% | Cons +47.0%
Price$30.47
Signal$33.42|-8.8%|2026-03-13 11:30:00
Headline: Capricor Therapeutics (CAPR) Reiterated at Overweight by Cantor Fitzgerald After Q4 Result
TargetsPT $62.00 | Cons $47.75
UpsideImp +85.5% | Cons +42.9%
Price$50.04
Signal$54.02|-7.4%|2026-03-13 11:22:00
Headline: Rubrik (RBRK) Reiterated at Overweight by Cantor Fitzgerald After Q4 Results
TargetsPT $85.00 | Cons $92.17
UpsideImp +57.3% | Cons +70.6%
Price$33.16
Signal$35.10|-5.5%|2026-03-13 11:14:00
Headline: Omnicell (OMCL) Reiterated at Buy by Benchmark After Investor, CEO Meet
TargetsPT $60.00 | Cons $55.25
UpsideImp +70.9% | Cons +57.4%
Price$10.43
Signal$10.90|-4.4%|2026-03-13 10:43:00
Headline: Elicio Therapeutics (ELTX) PT Raised to $17 at H.C. Wainwright
TargetsPT $17.00 | Cons $17.00
UpsideImp +56.0% | Cons +56.0%
Price$180.60
Signal$180.85|-0.1%|2026-03-16 13:53:00
Headline: Jefferies Reiterates Buy Rating on Capital One Financial (COF) after Feb credit metrics
TargetsPT $300.00 | Cons $275.50
UpsideImp +65.9% | Cons +52.3%
Price$23.67
Signal$23.67|0.0%|2026-01-13 13:16:00
Headline: BCE Inc. (BCE:CN) (BCE) PT Raised to Cdn$38 at RBC Capital
TargetsPT $38.00 | Cons $33.86
UpsideImp +60.5% | Cons +43.1%
Price$31.44
Signal$24.66|+27.5%|2026-01-30 14:20:35
Headline: SSR Mining price target raised to $38.50 from $34.50 at UBS
TargetsPT $38.50 | Cons $33.50
UpsideImp +56.1% | Cons +35.8%
Price$104.93
Signal$128.34|-18.2%|2026-02-04 12:19:53
Headline: Colliers International upgraded to Strong Buy from Outperform at Raymond James
TargetsPT $200.00 | Cons $188.00
UpsideImp +55.8% | Cons +46.5%
Price$17.34
Signal$20.08|-13.6%|2026-02-04 10:47:44
Headline: Capri Holdings price target raised to $32 from $31 at Barclays
TargetsPT $32.00 | Cons $25.73
UpsideImp +59.4% | Cons +28.1%
Price$56.65
Signal$42.43|+33.5%|2026-02-10 12:23:59
Headline: Xenon Pharmaceuticals price target raised to $66 from $60 at Stifel
TargetsPT $66.00 | Cons $55.75
UpsideImp +55.6% | Cons +31.4%
Price$14.00
Signal$19.02|-26.4%|2026-02-10 10:44:20
Headline: Grupo Aeromexico price target raised to $28 from $27 at Barclays
TargetsPT $28.00 | Cons $30.67
UpsideImp +47.2% | Cons +61.3%
Price$32.68
Signal$30.84|+6.0%|2026-02-18 13:10:51
Headline: Ideaya Biosciences price target raised to $52 from $49 at Wedbush
TargetsPT $52.00 | Cons $44.25
UpsideImp +68.6% | Cons +43.5%
Price$104.54
Signal$97.52|+7.2%|2026-02-18 10:17:21
Headline: Nebius initiated with a Buy at Compass Point
TargetsPT $150.00 | Cons $141.20
UpsideImp +53.8% | Cons +44.8%
Price$124.77
Signal$127.43|-2.1%|2026-02-24 05:23:00
Headline: Evercore ISI Reiterates Outperform Rating on Arista Networks (ANET)
TargetsPT $200.00 | Cons $183.00
UpsideImp +56.9% | Cons +43.6%
Price$55.55
Signal$60.26|-7.8%|2026-02-26 13:22:00
Headline: BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $104 at Canaccord
TargetsPT $104.00 | Cons $82.00
UpsideImp +72.6% | Cons +36.1%
Price$183.58
Signal$191.75|-4.3%|2026-02-26 11:29:00
Headline: Goldman Sachs Reiterates Buy Rating on salesforce.com (CRM)
TargetsPT $281.00 | Cons $299.00
UpsideImp +46.5% | Cons +55.9%
Price$55.55
Signal$60.47|-8.1%|2026-03-02 14:53:00
Headline: BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Freedom Capital Markets
TargetsPT $105.00 | Cons $85.43
UpsideImp +73.6% | Cons +41.3%
Price$87.62
Signal$95.68|-8.4%|2026-03-02 12:17:00
Headline: 'Shake Shack (SHAK) Hitting on All Cylinders'; PT Raised to $148 at Truist
TargetsPT $148.00 | Cons $118.00
UpsideImp +54.7% | Cons +23.3%
Price$23.91
Signal$30.95|-22.8%|2026-03-03 10:56:00
Headline: Ameresco (AMRC) PT Raised to $50 at Canaccord
TargetsPT $50.00 | Cons $42.57
UpsideImp +61.6% | Cons +37.5%
Price$65.28
Signal$74.40|-12.3%|2026-03-05 14:22:00
Headline: DA Davidson Reiterates Buy Rating on Euronet Worldwide (EEFT)
TargetsPT $112.00 | Cons $103.00
UpsideImp +50.5% | Cons +38.4%
Price$78.69
Signal$81.16|-3.0%|2026-03-06 13:03:00
Headline: Okta, Inc (OKTA) PT Raised to $134 at Bernstein SocGen Group
TargetsPT $134.00 | Cons $108.24
UpsideImp +65.1% | Cons +33.4%
Price$56.65
Signal$62.76|-9.7%|2026-03-09 19:52:00
Headline: Xenon Pharmaceuticals (XENE) PT Raised to $100 at Jefferies
TargetsPT $100.00 | Cons $76.67
UpsideImp +59.3% | Cons +22.2%
Price$85.86
Signal$80.88|+6.2%|2026-03-09 14:15:00
Headline: Dianthus Therapeutics (DNTH) PT Raised to $145 at Oppenheimer
TargetsPT $145.00 | Cons $101.00
UpsideImp +79.3% | Cons +24.9%
Price$32.00
Signal$29.97|+6.8%|2026-03-09 13:49:00
Headline: BTIG Reiterates Buy Rating on Rapport Therapeutics (RAPP): "see the X-TOLE2 readout as having no rea…
TargetsPT $47.00 | Cons $43.50
UpsideImp +56.8% | Cons +45.2%
Price$23.08
Signal$28.10|-17.9%|2026-03-10 20:05:00
Headline: Raymond James Starts Alumis Inc (ALMS) at Strong Buy
TargetsPT $46.00 | Cons $38.44
UpsideImp +63.7% | Cons +36.8%
Price$12.00
Signal$13.50|-11.1%|2026-03-11 13:46:00
Headline: UBS Reiterates Buy Rating on Surgery Partners (SGRY) Following Activist Letter to Shareholders
TargetsPT $21.00 | Cons $18.85
UpsideImp +55.6% | Cons +39.7%
Price$6.21
Signal$7.00|-11.3%|2026-03-12 18:55:00
Headline: Truist Securities Reiterates Hold Rating on Aveanna Healthcare Holdings Inc (AVAH) amid acquisition
TargetsPT $10.00 | Cons $11.25
UpsideImp +42.9% | Cons +60.7%
Price$36.86
Signal$38.39|-4.0%|2026-03-12 13:55:00
Headline: BofA Securities Reiterates Buy Rating on Dynatrace Inc. (DT): "risk/reward is very attractive"
TargetsPT $64.00 | Cons $51.47
UpsideImp +66.7% | Cons +34.1%
Price$55.55
Signal$59.86|-7.2%|2026-03-12 13:26:00
Headline: Jefferies Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN): "data looks viable and is a…
TargetsPT $103.00 | Cons $86.60
UpsideImp +72.1% | Cons +44.7%
Price$104.54
Signal$130.55|-19.9%|2026-03-16 16:12:00
Headline: Nebius Group (NBIS) PT Raised to $200 at DA Davidson
TargetsPT $200.00 | Cons $176.60
UpsideImp +53.2% | Cons +35.3%
Price$11.10
Signal$11.52|-3.6%|2026-03-17 13:57:00
Headline: Craig-Hallum stays Buy on Green Dot (GDOT): 'opportunity' as current stock indicates 0.68x TBV multi…
TargetsPT $18.00 | Cons $16.13
UpsideImp +56.3% | Cons +40.0%
Price$33.44
Signal$43.91|-23.8%|2026-03-17 12:42:00
Headline: Morgan Stanley stays Overweight on Celsius Holdings (CELH), estimates Alani growth in mid-80%s
TargetsPT $64.00 | Cons $67.25
UpsideImp +45.8% | Cons +53.2%
Price$40.37
Signal$44.76|-9.8%|2026-03-18 14:59:00
Headline: GDS Holdings (GDS) PT Raised to $67.50 at Macquarie as Chinese hyperscalers step up CapEx commitment…
TargetsPT $67.50 | Cons $62.17
UpsideImp +50.8% | Cons +38.9%
| ZVRA | Zevra Therapeutics, Inc. | Healthcare | Biotechnology | $539.6M | N/A | $26.00 | $8.90 | +194.8% | $24.67 | +179.7% | +4.2% | +046022-01 | |
| VIR | Vir Biotechnology, Inc. | Healthcare | Biotechnology | $1.5B | N/A | $15.00 | $5.89 | +150.8% | $13.50 | +125.8% | +54.0% | +046022-01 | |
| ALMS | Alumis Inc. Common Stock | Healthcare | Biotechnology | $2.8B | Alumis price target raised to $50 from $25 at Oppenheimer | $50.00 | $17.93 | +208.1% | $34.33 | +111.5% | +42.2% | 2026-01-06 | |
| ARDX | Ardelyx, Inc. | Healthcare | Biotechnology | $1.5B | Ardelyx price target raised to $19 from $16 at Raymond James | $19.00 | $7.75 | +171.6% | $15.60 | +123.0% | -14.9% | 2026-01-08 | |
| CGEM | Cullinan Therapeutics, Inc. | Healthcare | Medical - Pharmaceuticals | $862.8M | Cullinan Therapeutics price target raised to $27 from $26 at H.C. Wainwright | $27.00 | $11.13 | +150.7% | $31.00 | +187.8% | +32.4% | 2026-01-08 | |
| BRCC | BRC Inc. | Consumer Defensive | Packaged Foods | $243.6M | DA Davidson Reiterates Buy Rating on BRC Inc. (BRCC) | $2.50 | $0.97 | +151.6% | $2.50 | +151.6% | -21.7% | 2026-01-14 | |
| LEGN | Legend Biotech Corporation | Healthcare | Biotechnology | $3.5B | FDA draft guidance favorable for Legend Biotech, says RBC Capital | $66.00 | $23.42 | +180.6% | $62.17 | +164.3% | -20.1% | 2026-01-20 | |
| ATAI | Atai Beckley N.V | Healthcare | Medical - Pharmaceuticals | $689.4M | Atai Beckley initiated with a Buy at Guggenheim | $11.00 | $3.85 | +202.2% | $12.33 | +238.7% | +0.4% | 2026-01-20 | |
| IRD | Opus Genetics, Inc. | Healthcare | Biotechnology | $328.9M | Opus Genetics initiated with a Buy at BTIG | $7.00 | $2.26 | +233.3% | $7.00 | +233.3% | +120.1% | 2026-01-20 | |
| ARCT | Arcturus Therapeutics Holdings Inc. | Healthcare | Biotechnology | $227.8M | Arcturus Therapeutics initiated with a Buy at Roth Capital | $20.00 | $7.59 | +163.5% | $37.00 | +387.5% | +5.6% | 2026-01-22 | |
| GHRS | GH Research PLC | Healthcare | Biotechnology | $900.0M | GH Research price target raised to $40 from $33 at RBC Capital | $40.00 | $16.73 | +139.1% | $35.17 | +110.2% | -13.3% | 2026-01-23 | |
| RLMD | Relmada Therapeutics, Inc. | Healthcare | Biotechnology | $506.0M | Relmada Therapeutics assumed at Outperform from Market Perform at Leerink | $8.00 | $3.90 | +102.0% | $8.50 | +114.6% | +74.2% | 2026-01-23 | |
| NKTR | Nektar Therapeutics | Healthcare | Biotechnology | $1.5B | Piper Sandler on Nektar Therapeutics (NKTR): 'We See a Substantial Opportunity Into These De-Risked Data' | $105.00 | $37.18 | +188.9% | $119.00 | +227.4% | +109.2% | 2026-01-26 | |
| KRRO | Korro Bio, Inc. | Healthcare | Biotechnology | $119.8M | Korro Bio upgraded to Overweight from Neutral at Piper Sandler | $30.00 | $11.69 | +156.6% | $19.67 | +68.3% | +9.1% | 2026-01-28 | |
| DNTH | Dianthus Therapeutics, Inc. | Healthcare | Biotechnology | $3.3B | Dianthus price target raised to $125 from $62 at Oppenheimer | $125.00 | $53.36 | +134.8% | $80.20 | +50.7% | +61.3% | 2026-01-29 | |
| CATX | Perspective Therapeutics, Inc. | Healthcare | Medical - Devices | $332.2M | Perspective Therapeutics price target raised to $12 from $10 at H.C. Wainwright | $12.00 | $3.79 | +181.7% | $11.00 | +158.2% | +5.9% | 2026-01-30 | |
| ENGN | enGene Holdings Inc. | Healthcare | Biotechnology | $340.7M | enGene initiated with a Buy at Jefferies | $28.00 | $9.53 | +172.6% | $24.00 | +133.7% | -35.2% | 2026-01-30 | |
| CGEM | Cullinan Therapeutics, Inc. | Healthcare | Medical - Pharmaceuticals | $862.8M | Cullinan Therapeutics initiated with a Buy at Guggenheim | $30.00 | $12.71 | +150.8% | $30.83 | +157.8% | +19.2% | 2026-02-02 | |
| APP | AppLovin Corporation | Technology | Software - Application | $129.3B | AppLovin derating creates potential opportunity, says Morgan Stanley | $800.00 | $387.34 | +106.5% | $755.85 | +95.1% | -1.2% | 2026-02-04 | |
| CMPX | Compass Therapeutics, Inc. | Healthcare | Biotechnology | $747.4M | Compass Therapeutics price target raised to $13 from $10 at Canaccord | $13.00 | $6.33 | +102.5% | $10.50 | +63.6% | -15.8% | 2026-02-04 | |
| ZURA | Zura Bio Limited | Healthcare | Biotechnology | $383.0M | Zura Bio initiated with an Outperform at Wedbush | $15.00 | $6.27 | +149.6% | $15.00 | +149.6% | -2.0% | 2026-02-09 | |
| NKTR | Nektar Therapeutics | Healthcare | Biotechnology | $1.5B | Nektar price target raised to $165 from $135 at H.C. Wainwright | $165.00 | $56.00 | +213.6% | $131.40 | +149.7% | +44.5% | 2026-02-10 | |
| HOOD | Robinhood Markets, Inc. | Financial Services | Financial - Capital Markets | $61.0B | Bernstein Reiterates Outperform Rating on Robinhood Markets (HOOD) | $160.00 | $78.07 | +110.8% | $137.71 | +81.4% | -10.7% | 2026-02-11 | |
| APP | AppLovin Corporation | Technology | Software - Application | $129.3B | AppLovin price target raised to $775 from $750 at Scotiabank | $775.00 | $366.91 | +108.2% | $690.93 | +85.6% | +2.8% | 2026-02-12 | |
| VIR | Vir Biotechnology, Inc. | Healthcare | Biotechnology | $1.5B | Vir Biotechnology price target raised to $26 from $24 at Barclays | $26.00 | $7.50 | +248.1% | $20.50 | +174.4% | +23.3% | 2026-02-17 | |
| VSTM | Verastem, Inc. | Healthcare | Biotechnology | $387.5M | Verastem price target raised to $18 from $15 at Mizuho | $18.00 | $5.94 | +215.2% | $15.00 | +162.7% | -2.1% | 2026-02-19 | |
| NBIS | Nebius Group N.V. | Communication Services | Internet Content & Information | $25.1B | Nebius price target raised to $232 from $211 at Northland | $232.00 | $100.61 | +133.7% | $156.33 | +57.4% | +5.3% | 2026-02-23 | |
| VIR | Vir Biotechnology, Inc. | Healthcare | Biotechnology | $1.5B | Vir Biotechnology price target raised to $24 from $20 at Morgan Stanley | $24.00 | $10.42 | +223.0% | $20.67 | +178.2% | +24.0% | 2026-02-24 | |
| PLNT | Planet Fitness, Inc. | Consumer Cyclical | Leisure | $5.7B | Jefferies trims Planet Fitness price target, sees 'strong buying opportunity' | $175.00 | $79.87 | +111.8% | $134.00 | +62.2% | -13.1% | 2026-02-24 | |
| VIR | Vir Biotechnology, Inc. | Healthcare | Biotechnology | $1.5B | Vir Biotechnology (VIR) PT Raised to $20 at Leerink Partners | $20.00 | $9.32 | +114.5% | $20.57 | +120.6% | -1.2% | 2026-02-26 | |
| DYN | Dyne Therapeutics, Inc. | Healthcare | Biotechnology | $3.0B | Chardan Reiterates Buy Rating on Dyne Therapeutics (DYN) | $38.00 | $16.15 | +135.3% | $37.60 | +132.8% | +14.2% | 2026-03-02 | |
| SRAD | Sportradar Group AG | Technology | Software - Application | $5.0B | Truist Securities Reiterates Buy Rating on Sportradar Group AG (SRAD) following Q4 report | $32.00 | $17.67 | +81.1% | $32.00 | +81.1% | -5.9% | 2026-03-03 | |
| SGRY | Surgery Partners, Inc. | Healthcare | Medical - Care Facilities | $1.6B | Benchmark Reiterates Buy Rating on Surgery Partners (SGRY) Following Q4 Results | $30.00 | $13.92 | +123.7% | $22.33 | +66.5% | -10.5% | 2026-03-03 | |
| LRMR | Larimar Therapeutics, Inc. | Healthcare | Biotechnology | $398.8M | Larimar Therapeutics (LRMR) PT Raised to $12 at Wedbush | $12.00 | $5.51 | +119.2% | $9.50 | +73.5% | -14.9% | 2026-03-03 | |
| CRDO | Credo Technology Group Holding Ltd | Technology | Communication Equipment | $18.1B | Stifel Reiterates Buy Rating on Credo Technology Group Holding Ltd. (CRDO) Following Solid Print | $200.00 | $97.30 | +104.8% | $213.50 | +118.6% | +0.5% | 2026-03-03 | |
| SGP | SpyGlass Pharma, Inc. Common Stock | Healthcare | Biotechnology | $801.6M | Jefferies Starts SpyGlass Pharma (SGP) at Buy | $62.00 | $26.75 | +131.9% | $62.00 | +131.9% | -10.0% | 2026-03-03 | |
| DKNG | DraftKings Inc. | Consumer Cyclical | Gambling, Resorts & Casinos | $11.1B | DraftKings Inc. (DKNG) PT Raised to $50 at BMO Capital, Top Pick | $50.00 | $24.45 | +109.9% | $37.61 | +57.9% | -6.0% | 2026-03-03 | |
| ARCT | Arcturus Therapeutics Holdings Inc. | Healthcare | Biotechnology | $227.8M | '2026 will be a stock-moving year for ArthroCare (ARTC)'; PT Lowered at Piper Sandler | $25.00 | $7.33 | +236.9% | $22.50 | +203.2% | +8.0% | 2026-03-04 | |
| VIR | Vir Biotechnology, Inc. | Healthcare | Biotechnology | $1.5B | Vir Biotechnology (VIR) PT Raised to $20 at H.C. Wainwright | $20.00 | $9.25 | +119.1% | $21.29 | +133.2% | +0.9% | 2026-03-04 | |
| USGO | U.S. GoldMining Inc. | Basic Materials | Industrial Materials | $158.5M | US GoldMining Inc. (USGO) PT Raised to $30.75 at H.C. Wainwright | $30.75 | $13.49 | +130.9% | $30.75 | +130.9% | -10.7% | 2026-03-04 | |
| SOC | Sable Offshore Corp. | Energy | Oil & Gas Drilling | $1.5B | Jefferies Reiterates Buy Rating on Sable Offshore Corp. (SOC) amid DOJ formal opinion | $28.00 | $13.85 | +115.2% | $27.00 | +107.5% | +17.8% | 2026-03-05 | |
| VSTM | Verastem, Inc. | Healthcare | Biotechnology | $387.5M | Jefferies Reiterates Buy Rating on Verastem (VSTM); "catalyst-rich 2026" | $19.00 | $6.15 | +207.4% | $16.00 | +158.9% | -9.5% | 2026-03-05 | |
| RGTI | Rigetti Computing, Inc. | Technology | Computer Hardware | $4.5B | Rosenblatt Reiterates Buy Rating on Rigetti Computing Inc. (RGTI), raises rev estimate | $40.00 | $16.97 | +142.2% | $38.33 | +132.1% | -17.7% | 2026-03-05 | |
| ATAI | Atai Beckley N.V | Healthcare | Medical - Pharmaceuticals | $689.4M | Jefferies Reiterates Buy Rating on atai Life Sciences N.V (ATAI): "keen on ATAI's robust BPL-003 Phase IIb TRD results" | $10.00 | $3.39 | +195.0% | $11.75 | +246.6% | +7.8% | 2026-03-06 | |
| JBIO | Jade Biosciences, Inc. | Healthcare | Biotechnology | $523.6M | Jade Biosciences (JBIO) PT Raised to $40 at Stifel: "We like the setup for JADE101" | $40.00 | $14.05 | +184.4% | $31.00 | +120.4% | +14.1% | 2026-03-06 | |
| CN | Xtrackers MSCI All China Equity ETF | Financial Services | Asset Management - Global | $5.9M | Badger Infrastructure Solutions Ltd (BDGI:CN) (BADFF) PT Lowered at BMO Capital | $80.00 | $23.67 | +238.0% | $43.52 | +83.9% | 0.0% | 2026-03-06 | |
| GHRS | GH Research PLC | Healthcare | Biotechnology | $900.0M | GH Research PLC (GHRS) PT Raised to $32 at Needham | $32.00 | $15.93 | +108.7% | $35.67 | +132.6% | -5.4% | 2026-03-06 | |
| EDIT | Editas Medicine, Inc. | Healthcare | Biotechnology | $254.3M | Baird Reiterates Outperform Rating on Editas Medicine (EDIT) following earnings | $6.00 | $2.32 | +158.6% | $6.00 | +158.6% | +12.0% | 2026-03-09 | |
| QURE | uniQure N.V. | Healthcare | Biotechnology | $1.1B | Wells Fargo Upgrades uniQure BV (QURE) to Overweight | $60.00 | $17.99 | +239.3% | $41.80 | +136.4% | -3.2% | 2026-03-09 | |
| KLRS | Kalaris Therapeutics Inc | Healthcare | Biotechnology | $106.8M | Raymond James Reiterates Strong Buy Rating on Kalaris (KLRS) | $23.00 | $10.00 | +141.8% | $21.00 | +120.8% | -40.0% | 2026-03-09 | |
| ENGN | enGene Holdings Inc. | Healthcare | Biotechnology | $340.7M | Raymond James Reiterates Strong Buy Rating on Engene Holdings Inc. (ENGN) following Q1 results | $27.00 | $7.05 | +246.6% | $24.60 | +215.8% | -14.6% | 2026-03-09 | |
| CN | Xtrackers MSCI All China Equity ETF | Financial Services | Asset Management - Global | $5.9M | AltaGas Ltd. (ALA:CN) (ATGFF) PT Raised to Cdn$49 at BMO Capital | $49.00 | $23.67 | +107.0% | $39.09 | +65.1% | 0.0% | 2026-03-09 | |
| CLYM | Climb Bio, Inc. | Healthcare | Biotechnology | $487.2M | Raymond James Starts Climb Bio (CLYM) at Strong Buy | $25.00 | $7.33 | +241.1% | $18.00 | +145.6% | -2.5% | 2026-03-10 | |
| BNTX | BioNTech SE | Healthcare | Biotechnology | $22.3B | Truist Securities Reiterates Buy Rating on BioNTech (BNTX) following earnings, management changes | $155.00 | $83.89 | +84.8% | $138.71 | +65.3% | +5.8% | 2026-03-10 | |
| QTTB | Q32 Bio Inc. | Healthcare | Biotechnology | $74.3M | H.C. Wainwright Reiterates Buy Rating on Q32 Bio Inc. (QTTB): "2026 should be highlighted by key clinical data" | $13.00 | $5.99 | +117.0% | $13.00 | +117.0% | +0.9% | 2026-03-10 | |
| LEGN | Legend Biotech Corporation | Healthcare | Biotechnology | $3.5B | Truist Securities Reiterates Buy Rating on Legend Biotech Corp. (LEGN): "infer from comments that Raritan's full manufacturing slot capacity approved" | $70.00 | $19.56 | +257.9% | $58.60 | +199.6% | -3.9% | 2026-03-10 | |
| JMIA | Jumia Technologies AG | Consumer Cyclical | Specialty Retail | $423.6M | Craig-Hallum Reiterates Buy Rating on Jumia Technologies (JMIA): "we expect quarters to start to stack" | $18.00 | $7.93 | +122.1% | $17.33 | +113.8% | -15.6% | 2026-03-10 | |
| RPAY | Repay Holdings Corporation | Technology | Software - Infrastructure | $214.3M | DA Davidson Reiterates Buy Rating on Repay (RPAY) Following Q4 Results | $9.00 | $3.04 | +187.1% | $6.83 | +117.9% | -21.9% | 2026-03-10 | |
| GHRS | GH Research PLC | Healthcare | Biotechnology | $900.0M | GH Research PLC (GHRS) PT Raised to $34 at Guggenheim | $34.00 | $15.76 | +115.0% | $36.50 | +130.9% | -8.2% | 2026-03-10 | |
| ZVRA | Zevra Therapeutics, Inc. | Healthcare | Biotechnology | $539.6M | Zevra Therapeutics, Inc. (ZVRA) PT Raised to $23 at Guggenheim | $23.00 | $11.06 | +108.5% | $24.25 | +119.9% | -16.7% | 2026-03-10 | |
| SPRY | ARS Pharmaceuticals, Inc. | Healthcare | Biotechnology | $775.5M | ARS Pharmaceuticals Inc (SPRY) PT Raised to $26 at Leerink Partners | $26.00 | $8.86 | +180.2% | $29.33 | +216.1% | -15.8% | 2026-03-10 | |
| MLYS | Mineralys Therapeutics, Inc. | Healthcare | Biotechnology | $1.7B | H.C. Wainwright Reiterates Buy Rating on Mineralys Therapeutics, Inc. (MLYS) | $56.00 | $28.43 | +105.7% | $54.00 | +98.3% | -4.5% | 2026-03-10 | |
| ARDX | Ardelyx, Inc. | Healthcare | Biotechnology | $1.5B | Leerink Partners Reiterates Outperform Rating on Ardelyx, Inc (ARDX) following conference | $17.00 | $5.66 | +200.3% | $17.00 | +200.4% | +5.1% | 2026-03-12 | |
| VKTX | Viking Therapeutics, Inc. | Healthcare | Biotechnology | $3.9B | Jefferies Reiterates Buy Rating on Viking Therapeutic (VKTX): "VKTX is in an execution mode this year" | $101.00 | $35.47 | +184.8% | $103.00 | +190.4% | -5.2% | 2026-03-12 | |
| LXRX | Lexicon Pharmaceuticals, Inc. | Healthcare | Biotechnology | $680.0M | H.C. Wainwright Reiterates Buy Rating on Lexicon Pharmaceuticals (LXRX): "significant upside potential exists" | $6.00 | $1.72 | +252.5% | $6.00 | +252.5% | -5.7% | 2026-03-12 | |
| PHAR | Pharming Group N.V. | Healthcare | Biotechnology | $1.1B | H.C. Wainwright Reiterates Buy Rating on Pharming Group (PHAR): "well positioned to drive value" | $37.00 | $15.14 | +137.5% | $39.50 | +153.5% | +6.5% | 2026-03-12 | |
| RARE | Ultragenyx Pharmaceutical Inc. | Healthcare | Biotechnology | $2.1B | Leerink Partners Reiterates Outperform Rating on Ultragenyx Pharma (RARE): "encouraged by this clinical win" | $60.00 | $21.71 | +180.9% | $49.90 | +133.6% | +1.7% | 2026-03-12 | |
| TNYA | Tenaya Therapeutics, Inc. | Healthcare | Biotechnology | $110.2M | Leerink Partners Reiterates Outperform Rating on Tenaya Therapeutics Inc (TNYA): "remains on track to share interim data" | $2.00 | $0.89 | +110.5% | $2.33 | +145.3% | -30.4% | 2026-03-12 | |
| LFMD | LifeMD, Inc. | Healthcare | Medical - Pharmaceuticals | $168.7M | LifeMD Inc (LFMD) PT Raised to $10 at Freedom Capital Markets | $10.00 | $3.94 | +157.7% | $8.50 | +119.1% | -9.7% | 2026-03-12 | |
| CDXS | Codexis, Inc. | Healthcare | Biotechnology | $158.1M | Stifel Reiterates Buy Rating on Codexis, Inc. (CDXS): "remains an interesting small cap idea" | $5.00 | $1.71 | +194.1% | $5.00 | +194.1% | +2.4% | 2026-03-12 | |
| SANA | Sana Biotechnology, Inc. | Healthcare | Biotechnology | $798.2M | Morgan Stanley Reiterates Overweight Rating on Sana Biotechnology (SANA) after "meaningful platform level de-risking event" | $12.00 | $3.36 | +257.1% | $9.00 | +167.9% | -11.0% | 2026-03-13 | |
| SOTK | Sono-Tek Corporation | Technology | Hardware, Equipment & Parts | $63.3M | Sono-Tek (SOTK) PT Raised to $8.50 at Oak Ridge Financial | $8.50 | $4.19 | +102.9% | $8.50 | +102.9% | -3.8% | 2026-03-13 | |
| LPRO | Open Lending Corporation | Financial Services | Financial - Credit Services | $140.1M | DA Davidson Reiterates Buy Rating on Open Lending (LPRO) | $4.00 | $1.45 | +176.8% | $4.00 | +176.8% | -18.0% | 2026-03-13 | |
| COWN | Cowen Inc. | Financial Services | Financial - Capital Markets | $1.1B | ServiceTitan (TTAN) PT Raised to $135 at TD Cowen | $135.00 | $38.99 | +246.2% | $106.67 | +173.6% | 0.0% | 2026-03-13 | |
| CNTY | Century Casinos, Inc. | Consumer Cyclical | Gambling, Resorts & Casinos | $41.5M | Stifel Reiterates Buy Rating on Century Casinos (CNTY) following Q4 report | $3.00 | $1.31 | +117.4% | $2.50 | +81.2% | +2.2% | 2026-03-13 | |
| ACIU | AC Immune S.A. | Healthcare | Biotechnology | $277.8M | Jefferies Reiterates Buy Rating on AC Immune SA (ACIU): '2025 financials largely immaterial' | $7.00 | $3.02 | +132.9% | $7.00 | +132.9% | -9.2% | 2026-03-13 | |
| RLAY | Relay Therapeutics, Inc. | Healthcare | Biotechnology | $2.1B | Relay Therapeutics (RLAY) PT Raised to $22 at Guggenheim | $22.00 | $10.36 | +103.4% | $16.33 | +51.0% | +8.2% | 2026-03-13 | |
| KRRO | Korro Bio, Inc. | Healthcare | Biotechnology | $119.8M | Raymond James Upgrades Korro Bio Inc. (KRRO) to Outperform | $23.00 | $12.80 | +100.0% | $20.29 | +76.4% | +10.9% | 2026-03-13 | |
| PRTA | Prothena Corporation plc | Healthcare | Biotechnology | $532.4M | Prothena (PRTA) Reiterated at Market Outperform by Citizens After Fireside Chat | $19.00 | $9.21 | +104.1% | $24.83 | +166.7% | +6.2% | 2026-03-13 | |
| VNET | VNET Group, Inc. | Technology | Information Technology Services | $2.2B | VNET Group Inc (VNET) PT Raised to $23.55 at Jefferies, 'Growth to Accelerate', 'Still our top pick' | $23.55 | $9.53 | +149.2% | $23.55 | +149.2% | -11.5% | 2026-03-16 | |
| NBP | NovaBridge Biosciences | Healthcare | Biotechnology | $288.1M | H.C. Wainwright Reiterates Buy Rating on NovaBridge Biosciences (NBP) following FDA meeting feedback | $9.00 | $2.90 | +214.7% | $9.00 | +214.7% | -12.6% | 2026-03-16 | |
| CLYM | Climb Bio, Inc. | Healthcare | Biotechnology | $487.2M | Truist Securities Starts Climb Bio (CLYM) at Buy | $17.00 | $7.12 | +138.8% | $17.67 | +148.2% | +0.4% | 2026-03-17 | |
| CATX | Perspective Therapeutics, Inc. | Healthcare | Medical - Devices | $332.2M | Truist Reiterates Buy Rating on Perspective Therapeutics Inc (CATX) | $12.00 | $4.95 | +135.8% | $12.20 | +139.7% | -11.4% | 2026-03-17 | |
| GPCR | Structure Therapeutics Inc. | Healthcare | Biotechnology | $3.1B | Structure Therapeutics (GPCR) PT Raised to $145 at BMO Capital | $145.00 | $56.15 | +154.9% | $116.71 | +105.2% | -4.8% | 2026-03-17 | |
| BCYC | Bicycle Therapeutics plc | Healthcare | Biotechnology | $340.4M | Morgan Stanley on Bicycle Therapeutics (BCYC): program deprioritization 'disappointing,' but 'right call' | $13.00 | $5.07 | +153.4% | $11.00 | +114.4% | -4.2% | 2026-03-17 | |
| CTMX | CytomX Therapeutics, Inc. | Healthcare | Biotechnology | $757.4M | CytomX Therapeutics (CTMX) PT Raised to $16 at Jefferies: 'buying opportunity here' | $16.00 | $4.40 | +247.4% | $11.60 | +151.9% | -3.4% | 2026-03-18 | |
| GHRS | GH Research PLC | Healthcare | Biotechnology | $900.0M | Guggenheim Reiterates Buy Rating on GH Research PLC (GHRS) Post Mgmt Call | $29.00 | $13.68 | +83.5% | $34.20 | +116.4% | -8.2% | 2026-01-05 | |
| CMPX | Compass Therapeutics, Inc. | Healthcare | Biotechnology | $747.4M | Raymond James Reiterates Outperform Rating on Compass Therapeutics (CMPX) | $9.00 | $5.46 | +84.0% | $9.67 | +97.7% | +10.5% | 2026-01-06 | |
| DNTH | Dianthus Therapeutics, Inc. | Healthcare | Biotechnology | $3.3B | Dianthus price target raised to $63 from $56 at Truist | $63.00 | $38.96 | +65.4% | $69.00 | +81.1% | +125.4% | 2026-01-08 | |
| ONDS | Ondas Holdings Inc. | Technology | Communication Equipment | $4.2B | Ondas price target raised to $25 from $12 at H.C. Wainwright | $25.00 | $13.13 | +106.0% | $16.43 | +35.4% | -25.7% | 2026-01-20 | |
| CTMX | CytomX Therapeutics, Inc. | Healthcare | Biotechnology | $757.4M | CytomX Therapeutics price target raised to $10 from $6.50 at Piper Sandler | $10.00 | $5.37 | +85.5% | $8.75 | +62.3% | -17.5% | 2026-01-20 | |
| BMRN | BioMarin Pharmaceutical Inc. | Healthcare | Biotechnology | $10.7B | BioMarin upgraded to Buy from Hold at Canaccord | $98.00 | $56.31 | +79.5% | $82.92 | +51.9% | +1.8% | 2026-01-20 | |
| SRAD | Sportradar Group AG | Technology | Software - Application | $5.0B | Sportradar price target raised, named a Best Idea for 2026 at Guggenheim | $35.00 | $18.57 | +91.8% | $32.00 | +75.3% | -8.9% | 2026-01-22 | |
| RLAY | Relay Therapeutics, Inc. | Healthcare | Biotechnology | $2.1B | Relay Therapeutics upgraded to Outperform from Perform at Oppenheimer | $14.00 | $7.59 | +88.4% | $13.50 | +81.7% | +57.5% | 2026-01-26 | |
| MBX | MBX Biosciences, Inc. Common Stock | Healthcare | Biotechnology | $1.1B | MBX Biosciences initiated with an Overweight at Barclays | $66.00 | $36.07 | +83.0% | $53.33 | +47.9% | -7.5% | 2026-01-27 | |
| KRRO | Korro Bio, Inc. | Healthcare | Biotechnology | $119.8M | Korro Bio upgraded to Overweight from Neutral at Cantor Fitzgerald | $21.00 | $10.74 | +95.5% | $21.50 | +100.2% | +18.7% | 2026-01-27 | |
| ARDX | Ardelyx, Inc. | Healthcare | Biotechnology | $1.5B | Ardelyx price target raised to $15 from $8 at Jefferies | $15.00 | $7.89 | +92.3% | $15.50 | +98.7% | -23.7% | 2026-01-27 | |
| CTMX | CytomX Therapeutics, Inc. | Healthcare | Biotechnology | $757.4M | CytomX Therapeutics price target raised to $10 from $8 at Barclays | $10.00 | $5.67 | +64.7% | $10.00 | +64.7% | -26.7% | 2026-02-04 | |
| AERO | Grupo Aeroméxico, S.A.B. de C.V. | Industrials | Airlines, Airports & Air Services | $2.0B | Grupo Aeromexico price target raised to $32 from $28 at Barclays | $32.00 | $20.51 | +56.1% | $31.33 | +52.8% | -31.7% | 2026-02-19 | |
| NVDA | NVIDIA Corporation | Technology | Semiconductors | $4.3T | Cantor Fitzgerald Reiterates Overweight Rating on NVIDIA (NVDA), Expects Beat and Raise Quarter | $400.00 | $191.55 | +109.2% | $272.54 | +42.6% | -8.5% | 2026-02-23 | |
| PICS | PicS N.V. | Technology | Software - Infrastructure | $1.4B | PicPay initiated with an Outperform at Mizuho | $30.00 | $15.61 | +91.0% | $23.67 | +50.7% | -32.9% | 2026-02-23 | |
| MDXG | MiMedx Group, Inc. | Healthcare | Biotechnology | $566.8M | Citizens Starts MiMedx Group (MDXG) at Market Outperform | $10.00 | $5.33 | +93.4% | $10.00 | +93.4% | -26.2% | 2026-02-23 | |
| JOBY | Joby Aviation, Inc. | Industrials | Airlines, Airports & Air Services | $8.0B | H.C. Wainwright Upgrades Joby Aviation Inc (JOBY) to Buy | $18.00 | $10.23 | +83.3% | $15.30 | +55.8% | -17.0% | 2026-02-26 | |
| DNLI | Denali Therapeutics Inc. | Healthcare | Biotechnology | $3.1B | Jefferies Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI) | $40.00 | $21.00 | +90.5% | $34.40 | +63.8% | -5.9% | 2026-03-02 | |
| PROP | Prairie Operating Co. | Financial Services | Financial - Capital Markets | $120.2M | Clear Street Reiterates Buy Rating on Prairie Operating Co (PROP) amid CEO resignation | $3.50 | $1.65 | +95.5% | $2.75 | +53.6% | +33.5% | 2026-03-03 | |
| BMRN | BioMarin Pharmaceutical Inc. | Healthcare | Biotechnology | $10.7B | BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Barclays | $105.00 | $58.53 | +75.8% | $85.43 | +43.0% | -7.0% | 2026-03-03 | |
| OUST | Ouster, Inc. | Technology | Hardware, Equipment & Parts | $1.2B | Ouster Inc. (OUST) PT Raised to $40 at Oppenheimer | $40.00 | $21.72 | +97.5% | $37.00 | +82.7% | -7.3% | 2026-03-03 | |
| OCS | Oculis Holding AG | Healthcare | Biotechnology | $1.5B | Oculis Holding AG (OCS) PT Raised to $50 at Stifel | $50.00 | $28.40 | +80.4% | $45.67 | +64.8% | -2.9% | 2026-03-04 | |
| PSIX | Power Solutions International, Inc. | Industrials | Industrial - Machinery | $1.5B | Power Solutions (PSIX) PT Raised to $107 at Freedom Capital Markets | $107.00 | $59.58 | +76.2% | $104.26 | +71.7% | +9.9% | 2026-03-04 | |
| HROW | Harrow Health, Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $1.3B | Harrow Health (HROW) PT Raised to $70 at H.C. Wainwright | $70.00 | $38.63 | +76.7% | $74.50 | +88.1% | -11.4% | 2026-03-04 | |
| NVDA | NVIDIA Corporation | Technology | Semiconductors | $4.3T | NVIDIA (NVDA) PT Raised to $360 at Tigress Financial Partners | $360.00 | $183.34 | +99.9% | $277.82 | +54.3% | -2.8% | 2026-03-05 | |
| MBX | MBX Biosciences, Inc. Common Stock | Healthcare | Biotechnology | $1.1B | Truist Securities Reiterates Buy Rating on MBX Biosciences Inc (MBX) | $50.00 | $27.94 | +73.7% | $55.33 | +92.3% | +15.9% | 2026-03-09 | |
| PLNT | Planet Fitness, Inc. | Consumer Cyclical | Leisure | $5.7B | Morgan Stanley Reiterates Overweight Rating on Planet Fitness (PLNT) amid CFO transition | $117.00 | $76.29 | +52.2% | $132.43 | +72.3% | -6.6% | 2026-03-10 | |
| SEPN | Septerna, Inc. | Healthcare | Biotechnology | $1.1B | Cantor Fitzgerald Reiterates Overweight Rating on Septerna Inc (SEPN) | $60.00 | $28.02 | +113.8% | $39.00 | +39.0% | -12.7% | 2026-03-10 | |
| CGEM | Cullinan Therapeutics, Inc. | Healthcare | Medical - Pharmaceuticals | $862.8M | Cullinan Oncology Inc. (CGEM) PT Raised to $28 at Stifel | $28.00 | $14.91 | +85.4% | $30.43 | +101.4% | -5.6% | 2026-03-10 | |
| DDD | 3D Systems Corporation | Technology | Computer Hardware | $268.0M | 3D Systems (DDD) PT Raised to $5 at Cantor Fitzgerald Following 'Respectable' Q4 Results | $5.00 | $2.45 | +98.4% | $5.00 | +98.4% | -27.2% | 2026-03-10 | |
| TEM | Tempus AI, Inc. | Healthcare | Medical - Healthcare Information Services | $8.1B | Tempus AI Inc (TEM) PT Raised to $95 at H.C. Wainwright | $95.00 | $50.90 | +82.6% | $87.11 | +67.4% | -10.8% | 2026-03-10 | |
| ORCL | Oracle Corporation | Technology | Software - Infrastructure | $411.7B | Deutsche Bank Reiterates Buy Rating on Oracle (ORCL) following Q3 results: "plenty to like in this print" | $300.00 | $163.09 | +84.8% | $280.79 | +73.0% | -11.8% | 2026-03-11 | |
| IRD | Opus Genetics, Inc. | Healthcare | Biotechnology | $328.9M | Craig-Hallum Reiterates Buy Rating on Opus Genetics (IRD): "continue to see significant upside opportunity" | $9.00 | $5.01 | +80.4% | $7.67 | +53.7% | -7.4% | 2026-03-11 | |
| JOBY | Joby Aviation, Inc. | Industrials | Airlines, Airports & Air Services | $8.0B | H.C. Wainwright Reiterates Buy Rating on Joby Aviation Inc (JOBY) | $18.00 | $9.74 | +76.0% | $15.75 | +54.0% | -20.3% | 2026-03-12 | |
| RWAY | Runway Growth Finance Corp. | Financial Services | Financial - Credit Services | $242.5M | Clear Street Reiterates Hold Rating on Runway Grouwth Finance Corp. (RWAY): 'We expect near-term portfolio churn' | $10.00 | $6.63 | +50.8% | $10.83 | +63.3% | +1.2% | 2026-03-13 | |
| NKTR | Nektar Therapeutics | Healthcare | Biotechnology | $1.5B | Nektar Therapeutics (NKTR) PT Raised to $140 at Oppenheimer | $140.00 | $73.25 | +91.1% | $136.40 | +86.2% | +3.8% | 2026-03-13 | |
| FNKO | Funko, Inc. | Consumer Cyclical | Leisure | $172.4M | Funko (FNKO) PT Raised to $6.50 at Texas Capital Securities | $6.50 | $4.13 | +56.2% | $6.50 | +56.3% | -25.2% | 2026-03-13 | |
| SVRA | Savara Inc. | Healthcare | Biotechnology | $1.1B | H.C. Wainwright Reiterates Buy Rating on Savara (SVRA): 'well positioned ahead of the August PDUFA date' | $10.00 | $5.23 | +93.4% | $10.25 | +98.2% | +8.3% | 2026-03-16 | |
| CN | Xtrackers MSCI All China Equity ETF | Financial Services | Asset Management - Global | $5.9M | Jefferies Reiterates Buy Rating on Forgent Power Solutions (FPS): 'encouraged' by performance amid capacity ramp | $44.00 | $23.67 | +85.9% | $37.66 | +59.1% | 0.0% | 2026-03-16 | |
| ELDN | Eledon Pharmaceuticals, Inc. | Healthcare | Biotechnology | $180.4M | Leerink Partners Reiterates Outperform Rating on Eledon Pharamceuticals (ELDN) | $5.00 | $2.74 | +82.8% | $5.00 | +82.8% | +10.1% | 2026-03-16 | |
| HROW | Harrow Health, Inc. | Healthcare | Drug Manufacturers - Specialty & Generic | $1.3B | BTIG Reiterates Buy Rating on Harrow Health (HROW) ahead of presentations | $63.00 | $34.48 | +81.7% | $72.20 | +108.2% | +1.2% | 2026-03-18 | |
| HPP | Hudson Pacific Properties, Inc. | Real Estate | REIT - Office | $290.5M | N/A | $26.00 | $11.07 | +140.1% | $11.92 | +10.1% | -50.6% | +046027-01 | |
| CN | Xtrackers MSCI All China Equity ETF | Financial Services | Asset Management - Global | $5.9M | CAE Inc. (CAE:CN) (CAE) PT Raised to Cdn$46 at RBC Capital | $46.00 | $23.67 | +94.3% | $35.19 | +48.7% | 0.0% | 2026-01-12 | |
| VSNT | Versant Media Group, Inc. Class A | Industrials | Advertising Agencies | $5.3B | Versant initiated with an Outperform at Wolfe Research | $52.00 | $34.11 | +53.4% | $52.00 | +53.3% | +8.4% | 2026-01-13 | |
| CRDO | Credo Technology Group Holding Ltd | Technology | Communication Equipment | $18.1B | Credo Technology price target raised to $260 from $220 at Barclays | $260.00 | $149.12 | +65.8% | $222.50 | +41.9% | -37.4% | 2026-01-15 | |
| MBX | MBX Biosciences, Inc. Common Stock | Healthcare | Biotechnology | $1.1B | MBX Biosciences Inc (MBX) PT Raised to $88 at Guggenheim | $88.00 | $40.53 | +115.1% | $50.80 | +24.2% | -18.5% | 2026-01-16 | |
| AU | AngloGold Ashanti Plc | Basic Materials | Gold | $51.5B | Citi Upgrades Endeavour Group Ltd (EDV:AU) to Buy | $200.00 | $99.03 | +102.9% | $106.40 | +8.0% | +3.4% | 2026-01-16 | |
| SRAD | Sportradar Group AG | Technology | Software - Application | $5.0B | Sportradar initiated with a Buy at Stifel | $28.00 | $18.25 | +53.4% | $32.00 | +75.3% | -8.9% | 2026-01-21 | |
| KRRO | Korro Bio, Inc. | Healthcare | Biotechnology | $119.8M | Korro Bio upgraded to Buy from Neutral at H.C. Wainwright | $20.00 | $13.31 | +71.1% | $19.67 | +68.3% | +9.1% | 2026-01-29 | |
| RAPP | Rapport Therapeutics, Inc. Common Stock | Healthcare | Biotechnology | $1.2B | Rapport Therapeutics initiated with an Overweight at Wells Fargo | $43.00 | $27.75 | +61.6% | $42.33 | +59.1% | +20.3% | 2026-02-02 | |
| HOOD | Robinhood Markets, Inc. | Financial Services | Financial - Capital Markets | $61.0B | Robinhood upgraded to Outperform from Peer Perform at Wolfe Research | $125.00 | $86.56 | +50.9% | $143.69 | +73.5% | -18.2% | 2026-02-09 | |
| KRRO | Korro Bio, Inc. | Healthcare | Biotechnology | $119.8M | Clear Street Upgrades Korro Bio Inc. (KRRO) to Buy | $18.00 | $11.24 | +60.2% | $19.43 | +72.9% | +13.5% | 2026-02-18 | |
| FOSL | Fossil Group, Inc. | Consumer Cyclical | Luxury Goods | $262.8M | Fossil initiated with an Outperform at Northland | $7.00 | $4.32 | +74.1% | $7.00 | +74.1% | +12.0% | 2026-02-19 | |
| MRVL | Marvell Technology, Inc. | Technology | Semiconductors | $92.0B | Marvell price target raised to $120 from $115 at UBS | $120.00 | $77.79 | +55.9% | $117.68 | +52.9% | +36.7% | 2026-02-23 | |
| PICS | PicS N.V. | Technology | Software - Infrastructure | $1.4B | BofA Securities Starts PicPay (PICS) at Buy | $27.00 | $17.76 | +67.2% | $24.50 | +51.7% | -34.7% | 2026-02-24 | |
| NVDA | NVIDIA Corporation | Technology | Semiconductors | $4.3T | Baird Reiterates Outperform Rating on NVIDIA (NVDA) following Coherent investment | $300.00 | $182.48 | +64.8% | $276.63 | +52.0% | -3.9% | 2026-03-02 | |
| SRPT | Sarepta Therapeutics, Inc. | Healthcare | Biotechnology | $2.3B | Jefferies Reiterates Buy Rating on Sarepta Therapeutics (SRPT); cites as potential "recovery story" | $30.00 | $15.87 | +87.8% | $22.89 | +43.3% | +38.7% | 2026-03-03 | |
| SOPH | SOPHiA GENETICS S.A. | Healthcare | Medical - Healthcare Information Services | $361.2M | BTIG Reiterates Buy Rating on Sophia Genetics SA (SOPH) | $7.00 | $4.10 | +70.7% | $7.00 | +70.7% | +22.9% | 2026-03-03 | |
| NVDA | NVIDIA Corporation | Technology | Semiconductors | $4.3T | NVIDIA (NVDA) PT Raised to $300 at Wedbush | $300.00 | $180.05 | +66.9% | $277.46 | +54.4% | -2.6% | 2026-03-03 | |
| GTN | Gray Media, Inc. | Communication Services | Broadcasting | $410.7M | Gray Television (GTN) PT Raised to $8 at Guggenheim | $8.00 | $5.23 | +51.8% | $8.00 | +51.8% | -16.7% | 2026-03-03 | |
| CMPX | Compass Therapeutics, Inc. | Healthcare | Biotechnology | $747.4M | Compass Therapeutics (CMPX) PT Raised to $9 at Jefferies | $9.00 | $5.53 | +62.8% | $11.00 | +98.9% | -2.3% | 2026-03-05 | |
| HOOD | Robinhood Markets, Inc. | Financial Services | Financial - Capital Markets | $61.0B | BofA Securities Reiterates Buy Rating on Robinhood Markets (HOOD) following Take Flight event | $122.00 | $80.56 | +52.9% | $132.13 | +65.6% | -15.1% | 2026-03-05 | |
| HEI-A | HEICO Corporation | Industrials | Aerospace & Defense | $33.3B | Jefferies Reiterates Buy Rating on HEICO (HEI) following 10-Q | $400.00 | $234.76 | +70.7% | $387.50 | +65.4% | -10.9% | 2026-03-05 | |
| MRVL | Marvell Technology, Inc. | Technology | Semiconductors | $92.0B | Marvell (MRVL) PT Raised to $164 at Craig-Hallum | $164.00 | $89.57 | +79.5% | $120.68 | +32.1% | +15.2% | 2026-03-06 | |
| JBI | Janus International Group, Inc. | Industrials | Construction | $661.7M | Benchmark Reiterates Buy Rating on Janus Int'l Group, Inc. (JBI), Estimates Unchanged | $9.00 | $5.29 | +65.1% | $9.00 | +65.1% | -12.6% | 2026-03-06 | |
| ADEA | Adeia Inc. | Technology | Software - Application | $2.7B | Adeia (ADEA) PT Raised to $40 at Rosenblatt following AMD agreement | $40.00 | $22.31 | +84.4% | $30.00 | +38.3% | +14.0% | 2026-03-09 | |
| RDNW | RideNow Group, Inc. | Consumer Cyclical | Auto - Dealerships | $142.3M | DA Davidson Reiterates Neutral Rating on RideNow Group (RDNW) as Momentum Continues | $6.00 | $3.71 | +61.7% | $6.00 | +61.7% | 0.0% | 2026-03-10 | |
| ONDS | Ondas Holdings Inc. | Technology | Communication Equipment | $4.2B | H.C. Wainwright Reiterates Buy Rating on Ondas Holdings Inc. (ONDS) | $17.00 | $10.01 | +71.0% | $15.63 | +57.2% | -9.3% | 2026-03-10 | |
| TDOC | Teladoc Health, Inc. | Healthcare | Medical - Healthcare Information Services | $919.6M | Deutsche Bank Upgrades Teladoc (TDOC) to Buy | $11.00 | $5.57 | +97.3% | $7.90 | +41.7% | -7.5% | 2026-03-10 | |
| SRPT | Sarepta Therapeutics, Inc. | Healthcare | Biotechnology | $2.3B | Sarepta Therapeutics (SRPT) PT Raised to $31 at Mizuho | $31.00 | $17.04 | +81.9% | $24.50 | +43.8% | +30.0% | 2026-03-12 | |
| LTH | Life Time Group Holdings, Inc. | Consumer Cyclical | Leisure | $5.8B | UBS Reiterates Buy Rating on Life Time Group Holdings Inc (LTH) | $43.00 | $25.74 | +64.2% | $41.33 | +57.8% | -0.2% | 2026-03-12 | |
| NVDA | NVIDIA Corporation | Technology | Semiconductors | $4.3T | Cantor Fitzgerald Reiterates Overweight Rating on NVIDIA (NVDA) Ahead of GTC Event | $300.00 | $183.14 | +62.7% | $278.59 | +51.1% | -5.1% | 2026-03-12 | |
| RYTM | Rhythm Pharmaceuticals, Inc. | Healthcare | Biotechnology | $5.9B | Rhythm Pharmaceuticals (RYTM) PT Raised to $143 at Wells Fargo | $143.00 | $91.15 | +58.9% | $140.18 | +55.7% | -3.2% | 2026-03-12 | |
| RLMD | Relmada Therapeutics, Inc. | Healthcare | Biotechnology | $506.0M | Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD): pullback 'a buying opprotunity' | $10.00 | $5.91 | +69.2% | $9.00 | +52.3% | +16.8% | 2026-03-13 | |
| CIGI | Colliers International Group Inc. | Real Estate | Real Estate - Services | $5.2B | Stifel Reiterates Buy Rating on Colliers International (CIGI) amid Savills acquisition of Eastdil | $175.00 | $107.97 | +62.1% | $182.60 | +69.1% | -2.8% | 2026-03-13 | |
| ORKA | Oruka Therapeutics, Inc. | Healthcare | Biotechnology | $1.9B | BTIG Reiterates Buy Rating on Oruka Therapeutics (ORKA): 'Commercial Precedents Continue to Read Through Positively to ORKA-001/2' | $73.00 | $40.00 | +92.0% | $55.86 | +47.0% | +34.6% | 2026-03-13 | |
| CAPR | Capricor Therapeutics, Inc. | Healthcare | Biotechnology | $1.4B | Capricor Therapeutics (CAPR) Reiterated at Overweight by Cantor Fitzgerald After Q4 Result | $62.00 | $30.50 | +85.5% | $47.75 | +42.9% | -8.8% | 2026-03-13 | |
| RBRK | Rubrik, Inc. | Technology | Software - Infrastructure | $10.1B | Rubrik (RBRK) Reiterated at Overweight by Cantor Fitzgerald After Q4 Results | $85.00 | $53.43 | +57.4% | $92.17 | +70.6% | -7.4% | 2026-03-13 | |
| OMCL | Omnicell, Inc. | Healthcare | Medical - Healthcare Information Services | $1.5B | Omnicell (OMCL) Reiterated at Buy by Benchmark After Investor, CEO Meet | $60.00 | $34.40 | +70.9% | $55.25 | +57.4% | -5.5% | 2026-03-13 | |
| ELTX | Elicio Therapeutics, Inc. | Healthcare | Biotechnology | $191.8M | Elicio Therapeutics (ELTX) PT Raised to $17 at H.C. Wainwright | $17.00 | $12.20 | +56.0% | $17.00 | +56.0% | -4.4% | 2026-03-13 | |
| COF | Capital One Financial Corporation | Financial Services | Financial - Credit Services | $112.3B | Jefferies Reiterates Buy Rating on Capital One Financial (COF) after Feb credit metrics | $300.00 | $180.77 | +65.9% | $275.50 | +52.3% | -0.1% | 2026-03-16 | |
| CN | Xtrackers MSCI All China Equity ETF | Financial Services | Asset Management - Global | $5.9M | BCE Inc. (BCE:CN) (BCE) PT Raised to Cdn$38 at RBC Capital | $38.00 | $23.67 | +60.5% | $33.86 | +43.1% | 0.0% | 2026-01-13 | |
| SSRM | SSR Mining Inc. | Basic Materials | Gold | $6.4B | SSR Mining price target raised to $38.50 from $34.50 at UBS | $38.50 | $22.83 | +56.1% | $33.50 | +35.8% | +27.5% | 2026-01-30 | |
| CIGI | Colliers International Group Inc. | Real Estate | Real Estate - Services | $5.2B | Colliers International upgraded to Strong Buy from Outperform at Raymond James | $200.00 | $134.62 | +55.8% | $188.00 | +46.5% | -18.2% | 2026-02-04 | |
| CPRI | Capri Holdings Limited | Consumer Cyclical | Luxury Goods | $2.1B | Capri Holdings price target raised to $32 from $31 at Barclays | $32.00 | $20.75 | +59.4% | $25.73 | +28.1% | -13.6% | 2026-02-04 | |
| XENE | Xenon Pharmaceuticals Inc. | Healthcare | Biotechnology | $4.5B | Xenon Pharmaceuticals price target raised to $66 from $60 at Stifel | $66.00 | $42.63 | +55.5% | $55.75 | +31.4% | +33.5% | 2026-02-10 | |
| AERO | Grupo Aeroméxico, S.A.B. de C.V. | Industrials | Airlines, Airports & Air Services | $2.0B | Grupo Aeromexico price target raised to $28 from $27 at Barclays | $28.00 | $19.05 | +47.2% | $30.67 | +61.3% | -26.4% | 2026-02-10 | |
| IDYA | IDEAYA Biosciences, Inc. | Healthcare | Biotechnology | $2.9B | Ideaya Biosciences price target raised to $52 from $49 at Wedbush | $52.00 | $30.92 | +68.6% | $44.25 | +43.5% | +6.0% | 2026-02-18 | |
| NBIS | Nebius Group N.V. | Communication Services | Internet Content & Information | $25.1B | Nebius initiated with a Buy at Compass Point | $150.00 | $101.80 | +53.8% | $141.20 | +44.8% | +7.2% | 2026-02-18 | |
| ANET | Arista Networks, Inc. | Technology | Computer Hardware | $157.1B | Evercore ISI Reiterates Outperform Rating on Arista Networks (ANET) | $200.00 | $129.50 | +57.0% | $183.00 | +43.6% | -2.1% | 2026-02-24 | |
| BMRN | BioMarin Pharmaceutical Inc. | Healthcare | Biotechnology | $10.7B | BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $104 at Canaccord | $104.00 | $61.11 | +72.6% | $82.00 | +36.1% | -7.8% | 2026-02-26 | |
| CRM | Salesforce, Inc. | Technology | Software - Application | $172.0B | Goldman Sachs Reiterates Buy Rating on salesforce.com (CRM) | $281.00 | $199.47 | +46.5% | $299.00 | +55.9% | -4.3% | 2026-02-26 | |
| BMRN | BioMarin Pharmaceutical Inc. | Healthcare | Biotechnology | $10.7B | BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Freedom Capital Markets | $105.00 | $59.74 | +73.7% | $85.43 | +41.3% | -8.1% | 2026-03-02 | |
| SHAK | Shake Shack Inc. | Consumer Cyclical | Restaurants | $3.5B | 'Shake Shack (SHAK) Hitting on All Cylinders'; PT Raised to $148 at Truist | $148.00 | $94.44 | +54.7% | $118.00 | +23.3% | -8.4% | 2026-03-02 | |
| AMRC | Ameresco, Inc. | Industrials | Engineering & Construction | $1.3B | Ameresco (AMRC) PT Raised to $50 at Canaccord | $50.00 | $27.90 | +61.5% | $42.57 | +37.5% | -22.8% | 2026-03-03 | |
| EEFT | Euronet Worldwide, Inc. | Technology | Software - Infrastructure | $2.7B | DA Davidson Reiterates Buy Rating on Euronet Worldwide (EEFT) | $112.00 | $74.22 | +50.5% | $103.00 | +38.4% | -12.3% | 2026-03-05 | |
| OKTA | Okta, Inc. | Technology | Software - Infrastructure | $13.3B | Okta, Inc (OKTA) PT Raised to $134 at Bernstein SocGen Group | $134.00 | $80.72 | +65.1% | $108.24 | +33.4% | -3.0% | 2026-03-06 | |
| XENE | Xenon Pharmaceuticals Inc. | Healthcare | Biotechnology | $4.5B | Xenon Pharmaceuticals (XENE) PT Raised to $100 at Jefferies | $100.00 | $62.76 | +59.3% | $76.67 | +22.2% | -9.7% | 2026-03-09 | |
| DNTH | Dianthus Therapeutics, Inc. | Healthcare | Biotechnology | $3.3B | Dianthus Therapeutics (DNTH) PT Raised to $145 at Oppenheimer | $145.00 | $79.23 | +79.3% | $101.00 | +24.9% | +6.2% | 2026-03-09 | |
| RAPP | Rapport Therapeutics, Inc. Common Stock | Healthcare | Biotechnology | $1.2B | BTIG Reiterates Buy Rating on Rapport Therapeutics (RAPP): "see the X-TOLE2 readout as having no readthrough" | $47.00 | $30.54 | +56.9% | $43.50 | +45.2% | +6.8% | 2026-03-09 | |
| ALMS | Alumis Inc. Common Stock | Healthcare | Biotechnology | $2.8B | Raymond James Starts Alumis Inc (ALMS) at Strong Buy | $46.00 | $28.10 | +63.7% | $38.44 | +36.8% | -17.9% | 2026-03-10 | |
| SGRY | Surgery Partners, Inc. | Healthcare | Medical - Care Facilities | $1.6B | UBS Reiterates Buy Rating on Surgery Partners (SGRY) Following Activist Letter to Shareholders | $21.00 | $13.48 | +55.6% | $18.85 | +39.7% | -11.1% | 2026-03-11 | |
| AVAH | Aveanna Healthcare Holdings Inc. | Healthcare | Medical - Care Facilities | $1.4B | Truist Securities Reiterates Hold Rating on Aveanna Healthcare Holdings Inc (AVAH) amid acquisition | $10.00 | $7.00 | +42.9% | $11.25 | +60.7% | -11.3% | 2026-03-12 | |
| DT | Dynatrace, Inc. | Technology | Software - Application | $11.1B | BofA Securities Reiterates Buy Rating on Dynatrace Inc. (DT): "risk/reward is very attractive" | $64.00 | $38.02 | +66.7% | $51.47 | +34.1% | -4.0% | 2026-03-12 | |
| BMRN | BioMarin Pharmaceutical Inc. | Healthcare | Biotechnology | $10.7B | Jefferies Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN): "data looks viable and is a positive sign" | $103.00 | $59.07 | +72.1% | $86.60 | +44.7% | -7.2% | 2026-03-12 | |
| NBIS | Nebius Group N.V. | Communication Services | Internet Content & Information | $25.1B | Nebius Group (NBIS) PT Raised to $200 at DA Davidson | $200.00 | $129.85 | +53.2% | $176.60 | +35.3% | -19.9% | 2026-03-16 | |
| GDOT | Green Dot Corporation | Financial Services | Financial - Credit Services | $616.8M | Craig-Hallum stays Buy on Green Dot (GDOT): 'opportunity' as current stock indicates 0.68x TBV multiple | $18.00 | $11.32 | +56.2% | $16.13 | +40.0% | -3.6% | 2026-03-17 | |
| CELH | Celsius Holdings, Inc. | Consumer Defensive | Beverages - Non-Alcoholic | $8.6B | Morgan Stanley stays Overweight on Celsius Holdings (CELH), estimates Alani growth in mid-80%s | $64.00 | $43.96 | +45.8% | $67.25 | +53.2% | -23.8% | 2026-03-17 | |
| GDS | GDS Holdings Limited | Technology | Information Technology Services | $7.8B | GDS Holdings (GDS) PT Raised to $67.50 at Macquarie as Chinese hyperscalers step up CapEx commitments | $67.50 | $44.49 | +50.8% | $62.17 | +38.9% | -9.8% | 2026-03-18 |